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Asthma and diffi cult asthma
Asthma is a heterogeneous disease in which patients have a history of 
respiratory symptoms, such as wheezing, shortness of breath, chest tightness 
and cough that vary over time and intensity and with variable expiratory airfl ow 
limitation (variable lung function) [1]. Asthma itself is characterized by airway 
obstruction, airway infl ammation and bronchial hyper responsiveness [2]. An 
estimated 300 million children and adults are affected by asthma worldwide. 
Although asthma is now a well treatable disease, its incidence is increasing over 
the years, making it still a major and increasing health problem for society [1]. 
To improve awareness, prevention and management of asthma worldwide, The 
Global Initiative for Asthma (GINA) was established in 1993 [1]. This initiative 
resulted in an improved guideline for treatment of asthma that can be used 
worldwide and adapted to individual needs of patients with asthma [1]. GINA 
published this guideline, The Global Strategy for Asthma and Prevention, which 
was revised in 2014 and updated in 2015. 
GINA [1] fi rst recommends assessing asthma control, treatment issues like 
adherence, avoidance of allergens and inhaler technique and the assessment 
of comorbid somatic and psychiatric symptoms and diseases. Second, GINA 
recommends, assessing severity of asthma symptoms by the level of treatment 
that is required to control symptoms and exacerbations. Appropriate control 
of disease for patients is described as the absence of troublesome symptoms 
during day and night, patients are in need of little or no reliever medication, 
have productive physically active lives, have normal or near normal lung function 
and are able to avoid serious asthma exacerbations. When the airways become 
infl amed which causes asthma symptoms by restricting or limiting the airfl ow 
to and from the lungs and results in decreased lung function and exacerbations, 
asthma is not under control.
GINA guidelines recommend a stepwise approach of fi ve steps of pharmacological 
treatment to achieve and maintain control over the disease [1]. In the fi rst three 
steps low doses of inhaled corticosteroids are preferred in combination with 
short-acting beta2-agonist (SABA). At step four and fi ve additional treatment 
with long acting beta2-agonist (LABA), Anti-IgE and/or oral corticosteroids are 
advocated. This pharmacological treatment is adjusted by stepping down or up 
according to asthma control. 
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Most patients are treated well according to these guidelines and achieve control 
over asthma symptoms. About 5% of asthma patients do not achieve optimal 
control and pose a substantial health problem for society. In the US 1,25 
million asthma patients [3] and 22 000 asthma patients in The Netherlands [4] 
cannot control their disease and consume a substantial part of the overall cost 
of asthma [5-8]. In addition, these patients are often extremely invalidated 
by their symptoms infl uencing both their daily life but also resulting in severe 
exacerbations and thus hospitalisations [6, 9-10]. Their asthma symptoms 
are not temporarily but chronically poor controlled which causes low quality of 
life [11].  Moreover, these patients are at risk of complications related to use 
of (high) doses of oral steroids [12], lung damage, their condition can be life 
threatening and also cause extreme anxiety [13]. 
This thesis mainly focuses on this diffi cult-to-treat patient group with asthma, 
i.e. specifi cally adult patients with diffi cult asthma (DA). Adult patients with 
diffi cult-to-treat asthma in this thesis are referred to as patients with diffi cult 
asthma (DA) only if, according to GINA guidelines, these patients do not achieve 
control at step 4 or 5 of GINA guidelines [1, 14]. This patient group constitutes a 
heterogeneous group with different subgroups of patients such as brittle asthma, 
and near fatal asthma [15, 16]. These are all subgroups with asthma with 
extreme diffi cult to control asthma symptoms. Specifi cally, in near fatal asthma, 
patients suffer from near fatal attacks that comprise of a disproportionate part 
of asthma morbidity [17]. 
The combination of the relatively low prevalence, heterogeneity and a defi nition 
that is based on pharmacological treatment makes DA an asthma population 
that is not only diffi cult-to-treat but also diffi cult to study. A better understanding 
of DA in order to create a basis for developing more adequate treatment 
opportunities is therefore the main aim of this thesis. 
A psychological approach in understanding diffi cult asthma
A pathophysiological approach has -as by default- been the fi rst choice in 
studying and treating DA, resulting however in an outcome which is far from 
optimal. This thesis focuses on a psychological approach to DA  -along with a 
pathophysiological approach- that may contribute to a better understanding of 
patients with DA and may constitute as such a better approach for an improved 
treatment. A psychological approach is the more relevant as the origin of ‘diffi cult’ 
asthma does not appear to be solely related to pure pathophysiological processes 
for all patients; some patients with DA do have severe bronchoconstriction 
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during exacerbation of their asthma while other patients during an exacerbation 
have no or negligible bronchoconstriction [18]. A psychological approach to 
DA is a point of view that corresponds with contemporary views of the role of 
psychological factors in chronical physical illness such as cardiovascular diseases 
[19]. It implies a question whether a pathophysiological approach is as self-
evident as it appears. 
In analogy with these other chronic medical conditions, it is especially interesting 
to study whether a psychological approach –or even better: a multidisciplinary 
approach- could improve the available knowledge in understanding the 
uncontrollability of asthma symptoms and therefore the severe and frequent 
exacerbations in DA. 
In this thesis we focus fi rst on co-morbid psychopathology, at both symptom 
and syndrome level and second on alexithymia –the inability to give words 
to emotions [20]- which are both probable factors that may contribute to the 
uncontrollability of asthma and therefore of the existence of DA. Psychopathology 
is a well-known concept in asthma while alexithymia seems to be a relatively 
new concept in asthma. Both lack empirical evidence in whether and how they 
are possibly related to DA.
Psychopathology
There is a difference between psychiatric symptoms and psychiatric syndromes. 
Psychiatric syndromes refer to a specifi c set of symptoms and course and 
can be diagnosed adequately (with a semi-structured interview) by trained 
professionals. Psychiatric symptomatology may also be assessed by self-report 
questionnaires, as is often the case in research. The main difference between 
psychopathology at symptom level compared to syndrome level is fi rst that a 
syndrome comprises of a combination of symptoms -often related to each other-, 
second the duration of symptoms is often long and of a specifi c minimal duration 
and third the impact of these symptoms on daily life have to be signifi cant. As 
these syndromes each represent a multitude of symptoms one may deduce 
that the presence of a psychiatric syndrome may complicate asthma in a more 
severe and/or complicated way. 
The prevalence of psychiatric syndromes in asthma is estimated at 31% [21], 
which is high compared to the overall prevalence of psychiatric syndromes (18%) 
in The Netherlands [22].  There is worldwide consensus that psychiatric symptoms 
like anxiety and depression are important complicating factors in asthma [23]. 
GINA guidelines [1] advise psychiatric symptoms to be screened for in patients 
with asthma in an early stage by their GPs and pulmonologists. Psychiatric 
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symptoms are known to have a negative impact in patients with asthma on 
adequate medication use, exacerbations and patients’ perceived wellbeing and 
vice versa asthma symptoms negatively infl uence psychiatric symptoms [24-
27]. The specifi c nature of the relation between psychiatric symptomatology 
and asthma is unclear, i.e. whether asthma or psychiatric symptoms are cause 
or consequence, however the relationship is probably bi-directional [28, 29]. 
Specifi cally anxiety and panic, for instance, may directly exacerbate symptoms 
by hyperventilation [30]. And the severity of asthma symptoms may also cause 
extreme anxiety and thus psychiatric symptomatology [31]. 
Until now research on psychopathology in asthma in general has been scarce 
and has mostly focused on psychiatric symptoms with the screening of self-
report questionnaires. Studies on psychiatric syndromes in asthma –to be 
diagnosed by specifi c structured interviews and observation- are much scarcer 
and have thus far mainly focused on anxiety and affective disorders, specifi cally 
post traumatic stress disorder (PTSD) [32-38]. Asthma has also been associated 
with alcohol/substance abuse and somatoform disorders [39]. Only one study 
[40] examined the prevalence of personality disorders in a population of asthma 
patients, which proved to be similar to the prevalence in the general population. 
The relationship between severity of asthma and psychopathology yields 
different results in different studies [2, 41-43], probably because of use of 
different instruments and heterogeneity of patients. 
Research on psychopathology (both at syndrome as well as symptom level) in 
DA is scarce. As a consequence it is unclear whether patients with severe asthma 
like DA present with high levels of psychopathology. It seems plausible that 
psychopathology is important in DA. Psychopathology is seen as a contributing 
factor in DA [18] although empirical evidence seems lacking. Knowledge 
concerning psychopathology in DA should be further developed, as it may 
constitute a signifi cant factor in the development and existence of DA. Therefore 
research on psychiatric symptoms and syndromes in DA is necessary; it may 
provide us with a better understanding of DA and may provide opportunities in 
diagnostics and treatment if psychiatric symptoms and/or syndromes are indeed 
highly prevalent in DA and if it infl uences health related wellbeing in patients.
Alexithymia
A less known and less studied concept that may also infl uence the uncontrollability 
of asthma symptoms in chronic conditions is alexithymia. Clinical practice and 
the existing management protocols for treating asthma, mention alexithymia 
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as a contributing concept in DA (44). However, also for alexithymia, empirical 
evidence seems lacking.
Literally alexithymia means without words for emotions [20]. It consists of 
four aspects: (1) diffi culty identifying and describing feelings; (2) diffi culty 
distinguishing feelings from bodily sensations; (3) reduction or absence of 
symbolic thinking; (4) utilitarian thinking without fantasy [45, 46]. Alexithymia 
is a dimensional concept that can be present from low negligible to high levels 
[46]. Patients with asthma are assumed to have high levels of alexithymia [45]. 
Alexithymia seems an important construct in asthma because patients with 
asthma need to be able to distinguish between feelings and bodily sensations 
[1]. Moreover, the emotional response to asthma symptoms defi nes the 
tendency to seek care and take medication [47]. Alexithymia can be regarded 
as an impairment that may lead on the one hand to the misinterpretation/
misperception of physical symptoms. On the other hand, alexithymia tends to 
infl uence illness perception and can lead to the overreporting and catastrophizing 
of somatic sensations. Both tendencies may result in poor asthma management 
[48]. 
Often overperception or blunted perception of symptoms occurs in patients with 
asthma [49]. Overperception or blunted perception occurs when the experience 
of dyspnea and of pathophysiological lung function does not correspond. Dyspnea 
or breathlessness is a subjective experience in which not pathophysiological but 
psychological factors and situational factors explain most of its variance [50]. In 
literature, patients with asthma are arranged in three categories according to the 
difference between dyspnea and lung function: normoperceivers, hypoperceivers 
and hyperperceivers [51]. In normoperceivers a marginal difference between 
dyspnea and lung function is seen. In hypoperceivers, however, there is blunted 
perception of symptoms, which can delay help seeking and lead to inadequate 
utilization of medication. Moreover, hypoperception is a potential risk factor 
for severe exacerbations [52] and can even lead to (avoidable) death. Instead 
of blunted perception, hyperperceivers are characterized by overperception of 
symptoms: More symptoms are reported than medically can be explained. This 
can lead to overutilization of health care and to iatrogenic side effects [53]. 
Alexithymia is on the one hand an old concept in asthma. On the other hand 
alexithymia did not evolve in asthma literature as it certainly did in other chronic 
somatic diseases. Recent studies in other somatic diseases such as diabetes 
and coronary heart disease show that not only alexithymia can be improved 
during treatment but also that patients with reduced alexithymia scores after 
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treatment have better somatic treatment outcomes that last over two years 
[54]. This could also imply treatment opportunities for patients with asthma, 
specifi cally DA.
Since alexithymia is hardly studied in asthma it is important to fi rst review which 
knowledge is already available on alexithymia in asthma and specifi cally DA
Specialised pulmonary rehabilitation
A psychological approach –along with pathophysiological approach -to DA can 
possibly create better treatment opportunities. It is however also interesting 
whether patients with DA benefi t from the existing treatment opportunities 
and whether psychiatric symptomatology complicates treatment and infl uences 
perceived wellbeing in DA or not. 
Treatment of asthma is, in general, provided by the general practitioner (GP) 
in a Primary Care setting. The GP can provide treatment according to GINA 
guidelines. However, if after 3-6 months at step 4 patients do not achieve 
control over asthma symptoms, if asthma symptoms are too severe or if there 
are doubts about diagnosis at an earlier step, referral to a pulmonologist is 
recommended besides stepping up in treatment [1]. The latter can – in case of 
poor treatment response – refer to an asthma rehabilitation centre [1]. Before 
referral to a specialised rehabilitation centre usually outpatient rehabilitation in 
a general hospital setting is prescribed unless asthma symptoms are too severe 
or if there are doubts about diagnosis. 
The American Thoracic Society (ATS) and (European Respiratory Society (ERS) 
have adopted the following defi nition of pulmonary rehabilitation: “Pulmonary 
rehabilitation is an evidence-based, multidisciplinary, and comprehensive 
intervention for patients with chronic respiratory diseases who are symptomatic 
and often have decreased daily life activities. Integrated into the individualized 
treatment of the patient, pulmonary rehabilitation is designed to reduce 
symptoms, optimize functional status, increase participation, and reduce health 
care costs through stabilizing or reversing systemic manifestations of the 
disease.” [55, page e14]. Existing pulmonary rehabilitation programmes in The 
Netherlands vary considerably in setting, intensity, content and duration. Most 
of these rehabilitation programmes are outpatient programmes along intensive 
inpatient programmes. 
Specifi cally specialised pulmonary rehabilitation programmes generally provide 
a scrupulous multidisciplinary assessment involving assessment of both somatic 
and psychosocial problems and their interaction over 4 days. Patients attending 
the rehabilitation have to be abstinent from smoking during rehabilitation. 
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Exclusion criteria for participation in the programme are also all disorders and 
diseases, both physical and psychiatric, that prevents a patient to participate in 
the treatment programme [56]. Specialised pulmonary rehabilitation is mostly 
inpatient. 
The most rigorous specialised pulmonary rehabilitation comprises a 
multidisciplinary inpatient programme of 3-months by a team of healthcare 
professionals, consisting of pulmonary physicians, specialized health care 
psychologists, respiratory nurses, physiotherapists, exercise therapists, 
dieticians, social workers, therapeutic recreation specialists and occupational 
therapists [55].  The rehabilitation centres offer a programme of 20-25 hours a 
week that is highly individualized with also group-based psychosocial counseling 
sessions [56]. The program further consists of exercise training, education, 
and optimization of medication. Specialized health care psychologists treat 
psychiatric symptoms and syndromes during the programme. If necessary, 
patients can be referred to more intensive treatment for psychiatric symptoms 
or syndromes before or after the programme.
The goal of the rehabilitation is to reduce symptoms, decrease disability and 
improve health related perceived wellbeing [55]. The goal is hence also to reduce 
exacerbations and hospitalizations. Interventions during the programme are 
targeted at both primary and secondary impairments of asthma, i.e. targeted at 
the direct and indirect impairments of asthma. However studies on the viability 
and outcome of these programmes for DA patients, specifi cally at longitudinal 
follow up, are very scarce.
As viability and outcome till now have not been systematically studied for 
patients with DA, further research and insight in therapeutic factors in such 
a rehabilation programme might contribute to optimal development of such 
programmes. 
AIMS AND OUTLINE OF THE THESIS
The main aim of this thesis was a better understanding of DA in order to 
create a basis for developing more adequate treatment opportunities from 
a psychological point of view. The existing recommendations for treating DA 
by GINA criteria incorporate a psychological point of view, however empirical 
support seems scarce. In addition, some patients still remain diffi cult-to-treat 
[1]. Two concepts that are considered complicating factors in asthma in both 
worldwide guidelines and clinical practice are psychiatric symptomatology /
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syndromes and alexithymia. Chapter 2, reports a review of studies on 
psychiatric symptomatology in DA evaluating the available empirical literature. 
In Chapter 3 the level of psychiatric symptomatology was studied in patients 
with DA along with the question if there is a relation with perceived wellbeing. 
Subsequently in Chapter 4, we specifi cally studied the prevalence of both 
major mental psychiatric disorders and personality disorders in DA. To generate 
more insight in a possible role of alexithymia in DA we fi rst reviewed in Chapter 
5 studies on the prevalence of alexithymia in asthma in general. Second, we 
reviewed studies on possible associations between alexithymia and severity of 
asthma, asthma control and quality of life. Third, we reviewed the studies on 
treatment and treatment outcome of alexithymia in asthma. We then studied 
in Chapter 6 whether patients with DA could benefi t from existent specialized 
pulmonary rehabilitation programmes with a special focus on psychiatric 
symptomatology. We therefore fi rst evaluated whether psychiatric symptoms in 
patients with DA do change during specialised pulmonary rehabilitation. Second, 
we assessed whether there was an association between psychiatric symptoms 
and a possible benefi t during the specialized pulmonary rehabilitation on health 
related wellbeing. Third, we evaluated whether a possible benefi t of specialised 
pulmonary rehabilitation persists at longitudinal follow-up. 
Finally, Chapter 7 concludes with the main fi ndings and a general discussion of 
this thesis. Specifi cally we will discuss suggestions to create better treatment 
opportunities for patients with DA from a psychological point of view in relation 
to the results of the current thesis.
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ABSTRACT
Objective: Within the asthma population, diffi cult asthma (DA) is a severe 
condition in which patients present with frequent exacerbations, hospitalizations 
and emergency room visits. The identifi cation and treatment of psychopathology 
is included in the management of DA. Psychopathology is supposed to predispose 
patients to DA or vice versa; psychopathology may develop as a consequence 
of DA. We reviewed the available literature on empirical fi ndings regarding 
psychopathology in adult patients with DA. 
Methods: Studies in English language journals using MEDLINE, Cochrane and 
PsycINFO databases, were retrieved by an electronic search published from 
1990 till July 2014. 
Results: Literature on psychopathology in DA is scarce. The search identifi ed 
16 articles of which only 6 articles were specifi cally about psychopathology 
in adult patients with DA. Almost half of the patients with DA had evidence 
of psychopathology at both syndrome and symptom level. Moreover, 
psychopathology appeared to be related to frequent exacerbations in patients 
with DA. 
Conclusions: This literature review suggests a high prevalence of 
psychopathology of patients with DA, although it remains unclear whether 
psychopathology occurs more often in DA compared to ‘‘stable asthma’’. More 
research is needed on a possible role of psychopathology on clinical signs and 
symptoms in DA.
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Asthma is a respiratory disease characterized by airway obstruction, airway 
infl ammation and bronchial hyper responsiveness [1,2]. Asthma is a common 
and increasing problem in our society [2,3]. About 8% of the adult population 
in Europe, North America and Australia has asthma [4]. Asthma can be a life-
threatening condition although usually, asthma is well controlled with standard 
treatment. Standard treatment is directed at maximizing the symptom-free 
periods and keeping the airways in the best possible physical state [2–4].
Treatment mostly involves the prescription of medication, avoiding asthma 
triggers and improving self-management strategies. Recent guidelines classify 
severity based on responsiveness to treatment [2,5]. Approximately 5% of 
patients with asthma have diffi cult asthma (DA) [6], as defi ned by the European 
Respiratory Society (ERS) task force [7], i.e. these patients do not reach an 
acceptable level of control at step 4 or 5 of prescribed treatment [3]. DA is 
defi ned as a failure to reduce the clinical manifestation of asthma symptoms 
despite maximal treatment [8–10]. As a result patients with DA have frequent 
exacerbations, hospital admissions and emergency room (ER) visits [8–10]. 
Patients with DA form a heterogeneous group with ‘‘uncontrollable symptoms’’. 
DA includes clinical subgroups with refractory asthma, near fatal asthma 
(NFA) [11], brittle asthma, nocturnal asthma, corticosteroid-resistant asthma, 
corticosteroid-dependent asthma and therapy-resistant asthma [6]. 
Although DA consists of a small group of patients, the impact on healthcare is 
signifi cant. A substantial part of the overall costs of asthma is consumed by patients 
with DA because of the many hospitalizations, ER visits and high medication use 
[3,8,12,13]. Moreover, DA infl uences the quality of life of patients themselves 
as well as their environment [8]. Ultimately DA can even lead to death. Reasons 
why asthma symptoms in these patients are diffi cult to manage are not well 
understood [3]. Management programs concerning the treatment of DA propose 
a stepwise management of the disease [6,14]. One step in the treatment of DA 
is the modifi cation of socioeconomic factors infl uencing disease control and the 
identifi cation and treatment of psychopathology, mental disorders as defi ned in 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) [15], the 
standard classifi cation used by mental health professionals. Psychopathology is 
suggested to obscure diagnostics and to complicate the treatment of asthma 
[14].
In the asthma population, the prevalence of psychopathology is signifi cantly 
higher compared to the general population [16–18], both at syndrome and 
symptom level.
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Feldman et al. [19] reported a prevalence of 46% of psychiatric diagnoses in 
asthma patients and the estimation of psychopathology in severe asthmatics 
ranges between 30 and 63% [20,21]. Asthmatic patients with psychopathology 
achieve fewer goals related to asthma control, have more asthma associated ER 
visits and use more medication, all independent of the severity of asthma and 
demographics. Moreover, these patients tend to report higher levels of asthma 
symptoms than expected by their pulmonary function [19].
Psychopathology can be both causal and secondary to DA. Psychopathology 
may predispose asthma patients directly to an exacerbation through 
psychophysiological processes or it may predispose asthma patients indirectly 
through factors like non-adherence, and maladaptive coping styles [6,22,23] 
or misinterpretation of symptoms resulting in improper asthma management 
leading to poor asthma control [19,21–25]. Vice versa asthma, especially 
with frequent exacerbations as in DA, may increase the risk of developing 
psychopathology.
In light of the management strategies prescribed [3,14,26], which involves 
treating psychopathology if diagnosed, there is a need to study the association 
between psychopathology and disease outcome [27]. However, to our knowledge, 
a review of evidence from the literature on the importance of the identifi cation 
and treatment of psychopathology in DA, has not yet been undertaken. 
Therefore, the aim of the present study was to review the literature with regard 
to (1) the prevalence of all psychopathology in general DA and in subcategories 
of DA; (2) evidence of associations between specifi c syndrome and symptoms 
of psychopathology and poor disease outcome in DA.
METHODS
Search
A comprehensive literature search of the PsycINFO database, MEDLINE database 
and Cochrane Library of English language abstracts was conducted on literature 
published from 1990 till July 2014 on psychopathology in DA. The search 
was conducted by pairing ‘‘diffi cult asthma’’ with keywords: psychological, 
psychology, psychiatric comorbidity, psychiatry, alexithymia, anxiety, panic, 
depression, affective, personality and psychopathology. Another search was 
conducted including subgroups of patients with DA by separately pairing 
‘‘refractory asthma’’, ‘‘near fatal asthma’’, ‘‘brittle asthma’’, ‘‘nocturnal asthma’’, 
‘‘corticosteroid- resistant asthma’’, ‘‘corticosteroid-dependent asthma’’, and 
‘‘therapy-resistant asthma’’ with the same keywords as mentioned above.
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Psychopathology can be described both at syndrome and symptom level. 
Psychopathological syndromes refer to a specifi c set of symptoms and can 
be diagnosed with a semi-structured interview by trained professionals. 
Psychopathology at symptom level can be determined by self-report 
questionnaires. Studies meeting the following criteria were included in this 
review: (a) participants were patients with DA as defi ned by the ERS task force 
[26], or were patients with asthma in the following subgroups; refractory asthma, 
near fatal asthma, brittle asthma, nocturnal asthma, corticosteroid-resistant 
asthma, corticosteroid-dependent asthma and therapy-resistant asthma, (b) 
participants were adults above 18 years, (c) psychopathology was studied at 
symptom level or syndrome level, measured with standardized instruments, 
(d) statistical analyses were well described and (e) studies were published in 
English.
Once an initial pool of articles was obtained, titles were screened on inclusion 
criteria. Abstracts from retained records were assessed to identify potentially 
relevant articles and duplicates were removed. For the remaining records full 
texts were obtained and articles were added to the search by cross-reference 
of full texts (Figure 1). All eligible papers were submitted to close reading and 
were coded by two readers (L. P. and A. P.) on the following characteristics: (a) 
number of participants, (b) asthma diagnosis of participants, (c) instruments 
used to measure psychopathology, (d) statistical analysis, (e) design of the 
study and (f) main fi ndings concerning psychopathology in DA. The results of 
the search are summarized in Tables 1, 2 and 3, describing results separately 
for DA in general and for each subgroup of DA.
RESULTS
The search initially identifi ed 267 hits, of which 54 were potentially relevant, 
as is shown in Figure 1. After applying the above mentioned inclusion criteria, 
removing duplicates and adding 3 articles by cross referencing, the search 
resulted in 16 articles. 
The studies are described in the tables; fi rst specifi cally for DA (Table 1), second 
for the subgroups NFA and brittle asthma (Tables 2 and 3, respectively) to give 
a nuanced picture of the studies on psychopathology in DA.
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Prevalence of all psychopathology in general DA
Four studies measured psychopathology at syndrome level (Tables 1, 2 and 
3). Heaney et al. [30,31] reported 48% psychopathology in DA, Garden et al. 
[42] 40% and Rocco et al. [37] reported 11.7%. At symptom level Robinson et 
al. [32] reported 46%, Campbell et al. [35] 43%, Garden et al. [42] 40%, Ten 
Brinke et al. [29] 20.4% and Van Veen et al. [33] 20.11% psychopathology in 
DA. Only Miles et al. [43] and Garden et al. [42] studied psychopathology in 
patients with DA in comparison to patients with stable asthma. Miles et al. [43] 
found higher prevalence rates of psychopathology while
Garden et al. [42] found no differences. 
Prevalence of all psychopathology in subcategories of DA
Anxiety and depression symptoms were studied in NFA-type of DA (Table 2). The 
reported prevalence rates ranged between 16.7% for state anxiety and 40.5% 
for depression [38]. Vázquez et al. [41] found no difference of prevalence of 
alexithymia (a personality trait which in a literal sense means ‘‘without words for 
emotions’’ [44]) between patients with NFA-type of DA and normal asthma while 
Plaza et al. [36] and Serrano et al. [40] reported more alexithymia in patients 
with NFA.
Associations between psychopathology syndrome and symptoms 
and poor disease outcome in DA
There were no studies on the relationship between disease outcome and 
psychopathology at syndrome level. At symptom level Heaney et al. [31] reported 
no relationship between psychopathology at symptom level and outcome in DA. 
Ten Brinke et al. [28] did report signifi cantly more GP visits, ER visits, exacerbations 
and hospitalizations in patients with DA who displayed more psychopathology at 
symptom level. Campbell et al. [34] studied psychopathology in DA compared 
to patients who died of asthma and found no differences between groups for 
psychopathology. And vice versa, DA patients with worse outcomes, i.e. more 
exacerbations, reported signifi cantly more psychopathology [29]. Alexithymia 
was associated with more hospitalizations [36] and more exacerbations [40] in 
patients with DA. Sández et al. [39] reported an association of reduced health-
related quality of life and depressive symptoms.
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Figure 1. Flow diagram of the literature search.
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Table 1. Psychopathology in DA
Study 
(fi rst author) Participants Instrument
Statistical 
Analysis Main Findings
Ten Brinke 2001 
[28]















Patients with psychiatric 
caseness have more:
GP visits p=0.02, 
ER visits p=0.01, 
exacerbations p=0.02, 
hospitalizations p=0.04
Ten Brinke 2005 
[29]












caseness in total of 136 
patients, 18.4% in 63 
patients. 
Patients with frequent 
exacerbations had higher 














48% psychiatric disorder, 
45% unrecognized. No 
difference for psychiatric 















49% ICD10 psychiatric 
diagnoses, 48% in DA, 
50% in non DA (ns). 
Anxiety and depression 
scores are higher in 
patients with ICD10 
diagnosis (p<0.01). No 
relation ICD10 diagnosis 
and outcome of asthma. 
Better outcome for QoL 
in NDA p<0.001, More 
depression in DA p<0.05
Robinson 2003 
[32]





10 patients had a major 
psychiatric contribution 
to asthma (17.9%), 
psychiatric caseness in 
26 patients (46%)
Van Veen 2008 
[33]






20.11 % psychiatric 
caseness. 
32% psychiatric caseness 
in obese patients, 16,9% 
psychiatric caseness 
in nonobese patients 
(p=0.10)
AQLQ= asthma quality of life score; DA = diffi cult asthma; ER = Emergency Room; GHQ = General 
Health Questionnaire; GP = General Practitioner; HADS = Hospital Anxiety and Depression Scale; 
ICD10 = International Classifi cation of Diseases 10; NDA = non diffi cult asthma; ns= non signifi can; 
PC = poorly compliant; QoL = Qualtiy of Life
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Table 2. Psychopathology in NFA
Study 













No difference in 















Positive correlation GHQ 
with morbidity (p<0.05) 
and stigmatization 
(p=0.02). No association 
GHQ and severity of 
asthma. 














24% alexithymia in NFA. 
More alexithymia in 
NFA (p<0.001). Higher 
mean TAS score in NFA 
(p=0.007). Alexithymia 
is associated with more 
hospitalizations in NFA 
and non NFA (p=0.036). 
No difference for 
dyspnea.







t-tests 11.7% minor psychiatric 












21.4% p-f, 40.5 % 
depression ,2.4% 
severe depression (of 
42 persons).16.7% 
state anxiety, 38.1% 
trait anxiety.  State 
anxiety is a risk factor 
for the prescription of 
oral steroids (p=0.015). 
Panic-fear and trait 




40 NFA SF-36, BDI, 





and p-f are associated 










TAS, GHQ-28 t-tests, mann 
whitney, chi2 
analyses, 
fi shers’ exact 
test logistic 
regression
36% alexithymia in 
NFA. More alexithymia 
(p=0.004) in NFA. 
Patients with NFA and 
alexithymia have more 
psychiatric caseness 
(p=0.002). Alexithymia 
is related to recurrent 
exacerbations (p=0.049)
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Table 2. Psychopathology in NFA
Study 
















36.4% trait anxiety. 
Higher levels of trait 
anxiety (p=0.001), 
depression (p=0.021). 
9% was alexithymic. 
There was no 
difference for TAS 
overall score, there 
were more problems 
in describing feelings 
in NFA (p=0.002). No 
differences for self 
management and 
adherence.
BDI = Beck Depression Inventory; BSSMA = Brooks self-report Scales of Medication Adherence; CDI 
= Cognitive Depression Index; GHQ = General Health Questionnaire; HDA= Hamilton depression and 
anxiety scales; HRQL= Health Related Quality of Life; HSPK = Hypothetical Scenarios of Practical 
Knowledge; IBQ = Illness Behaviour Questionnaire; MMPI = Minnesota Multiphasic Personality 
Inventory; NFA =  Near Fatal Asthma; p-f= panic and fear; p-f scale of ASC = panic fear scale of the 
Asthma Symptom Checklist; SF-36 = Short Form Health Survey; STAI = State Trait Anxiety Index; 
STAI-T = State Trait Anxiety Index, Trait; TAS = Toronto Alexithymia Scale; Zung AD = Zung Anxiety 
and depression scales
Table 3. Psychopathology in brittle asthma
Study 
(fi rst author)

















caseness and 40% 
current disorders; 3 
mood disorders, 1 
substance disorder, 6 
anxiety disorders and 
1 adjustment disorder. 
More current and past 
psychiatric disorders 
in brittle asthma 
(p=0.02). No difference 
in personality profi les or 
GHQ scores






Chi2 analyses More psychiatric 
caseness in brittle 
asthma (p=0.0002). 
More problems in living 
with asthma in brittle 
asthma (p=0.002). In 
brittle asthma 55.2 % of 
patients delayed seeking 
help, 20.7% in non 
brittle asthma
ASC = Asthma Symptom Checklist; BA =  Brittle asthma; EPI = Eysenck Personality Inventory ; GHQ 
= General Health Questionnaire; LAQ = Living with Asthma Questionnaire; SCID = Structured Clinical 
Interview for the Diagnostic and Statistical Manual of Mental Disorders
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Given the burden of DA and the role psychopathology plays in the treatment 
protocols of DA [2], it is remarkable that there are just few empirical literature 
studies on the association between psychopathology and DA. No studies 
were found on psychopathology in refractory asthma, nocturnal asthma, 
corticosteroid-resistant asthma, corticosteroid dependent asthma and therapy-
resistant asthma.
Results on the prevalence of psychopathology on both symptom and syndrome 
level in DA were mixed but there is some evidence to indicate a higher prevalence 
of psychopathology in DA. The mixed fi ndings are predominantly to be explained 
by the use of different instruments to assess psychopathology at different levels 
(symptoms versus syndrome). Another explanation could be the underestimation 
of symptoms in DA patients, possibly due to a high prevalence of alexithymia. 
Patients with alexithymia have diffi culty discriminating between emotions and 
physical symptoms, which will limit the ability to recognize psychopathology and 
can possibly result in insuffi cient asthma management.
There were no studies at syndrome level on the association between 
psychopathology and exacerbations, but four studies [28,29,36,40] showed 
a relationship between psychopathology and exacerbations in DA at symptom 
level. Patients with DA as well as psychopathology experienced more asthma 
hospitalizations and exacerbations in comparison to patients with DA and 
less psychopathology [28]. And vice versa, patients with more exacerbations 
reported more psychopathology compared to patients with fewer exacerbations 
[29]. Although the direction of this relationship is still speculative, it supports 
not only the importance of diagnosing psychopathology in DA, but also the 
extension of the medical examination after an exacerbation with a psychiatric 
evaluation. We can only speculate whether the treatment of psychopathology 
also positively infl uences outcome in DA.
Limitations
Although in the last two decades, substantial efforts have been made in 
appropriately defi ning asthma [2,3] and specifi cally DA, the concept of DA is still 
not well described which makes it a very heterogeneous group of patients to study. 
Because of the small number of studies as well as the heterogeneity between 
studies, the use of different instruments, small sample sizes, it is also diffi cult 
to make cross study comparisons. Also, it is a question whether it is acceptable 
to compare DA to NFA and brittle asthma since they are subcategories of DA.
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In summary, there is a higher prevalence rate of psychopathology in DA 
compared to the general population. Studies showing higher prevalence in DA 
compared to patients with stable asthma are equivocal. Alexithymia seems to 
be more common in DA compared to stable asthma and the general population 
but this association needs further consideration since all studies were performed 
in one country and only included patients/participants with a subcategory of DA 
(NFA). These fi ndings should be replicated in other ethnic groups with DA.
Clinical relevance and future recommendations
There is some preliminary evidence that psychiatric evaluation should be 
included in medical examinations for individuals with DA who present with an 
exacerbation. Subsequently, psychological interventions could become a more 
prominent part of the rehabilitation program. The treatment of psychopathology 
could have an infl uence on outcome in DA, but further study is needed to 
increase insight into the relevance of treating psychopathology in DA.
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ABSTRACT
Objective: Evidence on the prevalence of psychiatric symptoms in diffi cult 
asthma (DA) is scarce and contradictory. Psychiatric symptoms are seen 
important in the treatment of DA, however the relation with perceived wellbeing 
is also scarce and contradictory. The aim was to assess the level of psychiatric 
symptoms in DA and its relation to perceived wellbeing.
Methods: 102 patients with DA, submitted for inpatient rehabilitation, were 
assessed during multidisciplinary assessment in a specialized asthma care center. 
The level of psychiatric symptoms was assessed with the SCL-90, perceived 
wellbeing with the SGRQ. 
Results: Patients with DA reported signifi cantly higher levels of psychiatric 
symptoms in comparison to the general population, approaching those of the 
psychiatric population. Signifi cant and clinically relevant associations were found 
between psychiatric symptoms and perceived wellbeing and BMI, and between 
perceived wellbeing and BMI and exercise performance. Poor perceived wellbeing 
was most strongly associated with a higher level of psychiatric symptoms and 
in lesser extent to higher BMI and worse exercise performance. Psychiatric 
symptoms predicted worse perceived wellbeing. 
Conclusions: This study reveals a high level of psychiatric symptoms and 
therefore stresses the importance of detecting psychiatric symptoms in patients 
with DA. Early referral to medical psychologists or psychiatrists is recommended. 
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About 1.25 million people in the US have diffi cult asthma (DA) and are not 
responsive to maximal treatment according to international guidelines [1, 2]. 
These patients who have diffi culty controlling their asthma symptoms are a 
treatment challenge and a signifi cant clinical and fi nancial burden for the health 
care system [3]. Patients with DA have increased risk of future exacerbations, 
hospital admissions and emergency room (ER) visits which have a negative 
impact on patients’ perceived wellbeing [4-7]; for some patients DA can even 
lead to death. International guidelines on the treatment of asthma advocate 
a stepwise protocol (Global Initiative for Asthma, GINA1) [1], which mainly 
consists of fi ve steps of pharmacological treatment, with the last step including 
systemic corticosteroids (apart from general recommendations e.g. avoiding 
asthma triggers, adequate drug compliance etc.). The treatment of patients with 
DA follows the last two steps as described in the GINA guidelines. Nevertheless, 
these patients still experience invalidating symptoms that signifi cantly infl uence 
their daily life. 
DA is considered to be related to psychiatric symptoms [1,2]. Psychiatric 
symptoms are known to have a negative impact in patients with asthma on 
adequate medication use, exacerbations and patients’ perceived wellbeing and 
vice versa asthma symptoms negatively infl uence psychiatric symptoms [8-11]. 
Cause and consequence of psychiatric symptoms in asthma, and specifi cally DA, 
is unknown but is probably bi-directional [12]. Although psychiatric symptoms 
are associated with DA and are considered important in the treatment guidelines 
of DA [1, 6], research on the prevalence of psychiatric symptoms, especially 
the level of psychiatric symptoms, in DA is limited. Literature on psychiatric 
symptoms in DA and specifi cally the relation between psychiatric symptoms 
and patients’ perceived wellbeing is both scarce and contradictory [13-14]. 
Two preliminary studies show a prevalence of psychiatric cases of respectively 
21% [13] and 18% [14] in DA, which is comparable to the normal population. 
Robinson et al [15] however reported a higher prevalence of 46%. The former 
studies used cut-off scores to discriminate possible psychiatric cases and did 
not report the level of psychiatric symptoms. In addition, these studies did 
not compare the level of psychopathology to a norm group of the general and 
psychiatric population, which could give a more nuanced image of the severity 
of psychopathology. 
1 GINA guidelines refer to an evidence based strategy of asthma management and 
prevention and consist of 5 steps. Patients receive step-wise treatment until they 
reach an acceptable level of control of asthma symptoms.
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Therefore the present study aims fi rst at assessing the level of psychiatric 
symptoms in a cohort of patients with DA and comparing this level with norm 
scores of the general and psychiatric population. Second, we study the relation 
between psychiatric symptoms and patients’ perceived wellbeing, after correcting 
for confounders (i.e. obesity, age, female sex and physiological impairment) 
that are well known to negatively infl uence patients’ perceived wellbeing. 
METHODS
Setting
This cross-sectional study is conducted in ‘Revant Centre for Pulmonary 
Rehabilitation’, Breda, The Netherlands; a specialised tertiary asthma care centre 
that offers both inpatient and outpatient pulmonary rehabilitation. Asthmatic 
patients referred to inpatient rehabilitation have highly impaired health-related 
quality of life and no satisfactory response to prior medical and non-medical 
treatment by asthma specialists, often including outpatient rehabilitation [16,17]. 
These patients receive a comprehensive 3-months rehabilitation program on an 
inpatient basis by an interdisciplinary team of healthcare professionals, including 
pulmonologists and specialised health care psychologists, as recently described 
in detail elsewhere [16,17].  Patients enter the inpatient rehabilitation only after 
a multidisciplinary assessment of four days. Patients have to be abstinent from 
smoking if they want to participate in the rehabilitation program.  All patients 
met GINA criteria for DA and received pharmacological treatment at step 4 or 5 
of GINA criteria1. 
Participants and procedure
From November 2007 until June 2012, 193 asthma patients were referred for 
rehabilitation by pulmonologists from hospitals (fl ow diagram 1) for inpatient 
rehabilitation. After an initial screening by a pulmonologist and a pulmonary 
nurse on contra-indications as explained elsewhere [16] 126 patients entered 
a multidisciplinary assessment, including assessment by a psychologist, of 
four days to decide whether or not they were eligible for participation in the 
comprehensive treatment program. Eligibility was determined by ‘the impact 
of asthma’ on different dimensions of health status: physiological functioning, 
symptoms, activities, quality of life, health-care utilization during the previous 
year, motivation, commitment and feasibility [16]. Exclusion criteria for 
participation in the program were disorders and diseases both physical and 
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psychiatric that prevented a patient to participate in the treatment program. One 
patient was excluded because this patient did not use asthma medication. After 
assessment, 23 patients were excluded and did not enter rehabilitation resulting 
in a sample of 102 DA patients who entered the rehabilitation programme and 






Figure 1. Flow diagram
MEASUREMENTS
During the standard multidisciplinary assessment, a comprehensive set of 
parameters was collected, which was part of usual assessment [16]. Only the 
tests within de scope of this paper are described below. 
Psychiatric symptoms were measured with the Symptom Checklist (SCL90), a 90-
item multi-dimensional self-report symptom inventory that measures different 
types of psychiatric symptoms [18]. All items are rated on a fi ve point Likert scale 
ranging from ‘not at all’ to ‘extremely’ to indicate the extent to which a symptom 
has bothered or distressed someone in the past four weeks, the higher the 
score the higher the level of psychiatric symptoms. The checklist has an overall 
score (general psychiatric symptoms) and sub-scores on eight dimensions. The 
SCL90 has been used worldwide and validated in The Netherlands in men and 
women, the general population and in psychiatric samples, resulting in norm-
scores indicating ‘very low’ to ‘very high’ scores [18]. Total scores are used for 
the level of psychiatric symptoms. It should be remembered that scores in The 
Netherlands are not recoded to zero and scores range from 90 to 450. 
Patients’ perceived wellbeing was measured with the Saint George Respiratory 
Questionnaire (SGRQ), a 76 item questionnaire  with three sub-domains, i.g. 
symptoms, activity and impact [19]. A summary score is calculated by empirically 
weighted item scores. Scores range from 0 (no impairment) to 100 (maximal 
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impairment). The summary score is used in this study. The SGRQ has proven to 
be a valid and reliable instrument [19]. 
Physiological impairment was measured by airway obstruction and exercise 
performance. Lung function was measured by the ratio between the amount 
of air, which can be forcibly exhaled from the lungs in the fi rst second of a 
forced exhalation (FEV1, Forced Expiratory Volume in One Second). Exercise 
performance was measured by the maximal power output on a cycle ergometer 
(W-max) that has both good reliability and validity [20]. W-max measures 
the highest workload a patient can reach, and for how many seconds this can 
be maintained. People who are in good shape generally have higher W-max 
values (normalized for sex, age and height) and can therefore exercise more 
intensely than those with worse condition. In addition, demographics and BMI 
were assessed. 
Ethical Principles
This study was review board exempt since all assessments are part of usual care 
provided by the rehabilitation centre and all data were anonymized.  Patient’s 
informed consent was obtained for the utilization of the data for research 
purposes.
Statistical Methods
All statistical analyses were performed with the IBM SPSS Statistics for Windows 
Version 22.0 [21].
To determine the level and severity of psychiatric symptoms in participants, 
descriptive statistics were used to calculate means and standard deviations of the 
scores on the SCL90 and its subscales. Analyses were conducted separately for 
men and women, and displayed together with the average scores of the general 
population and a psychiatric sample for comparison. Differences between the 
average total scores of the population with DA, the general population and the 
psychiatric sample were analysed using one sample t-tests by taking the lowest 
mean score as hypothetical value. Differences between men and women for the 
SCL90 total score and its subscales were analysed using independent samples 
t-tests. 
In addition, the correlations between SCL90 total score, FEV1%, W-max, BMI 
and SGRQ were determined by Pearson correlation coeffi cients; p-values were 
considered statistical signifi cant when p < 0.05. However, since statistical 
signifi cance provides little information when calculating correlation coeffi cients, 
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clinical relevance was determined using Cohen’s criterion [22]. According to this 
criterion correlations of r ≥ 0.10 correspond with small, r > 0.30 with medium 
and r > 0.50 with large effect-sizes, the latter two are considered clinically 
relevant [22]. Multivariate linear regression analyses were performed with the 
SGRQ as dependent variable and the SCL-90 as independent variable. Several 
confounders (age, gender, BMI, W-max, FEV1%) were entered as separate 
blocks. The R-square statistic was determined to indicate the proportion of 
explained variance, and the F-change statistic was determined to indicate the 
signifi cance of adding separate blocks. In addition, a path analysis via regression 
analysis was performed using fi rst, a regression analysis with the SCL-90 as 
dependent variable and BMI and W-max as predictors. Second a regression 
analysis was performed with SGRQ as dependent variable and BMI, W-max and 
SCL-90 as predictors. The amount of variance that cannot be accounted for by 
the endogenous variables, including measurement error, are depicted in the 
unexplained variance, i.e. ‘e’ or error terms in the model. 
RESULTS
In the total sample of patients with DA, patients were more likely to be female 
(72%, 73/102) (table 1). Means and standard deviations (SD) of the scores 
on the subscales of the SCL-90 for men and women are shown in table 2. The 
scores are presented separately for males and females, together with the mean 
scores and SD’s of the general population and a psychiatric sample. Differences 
between subscales and total scores between males and females were calculated. 
There were no signifi cant differences between males and females for both scores 
on the subscales and the total score of the SCL-90 and for SGRQ total scores.
Differences between total scores for females and males for patients with DA, 
the general population and the psychiatric population were calculated. Female 
patients with DA reported signifi cantly higher SCL-90 total scores compared to 
the general population t(72) = 7,3, p<0.001 and signifi cantly lower total scores 
compared to the psychiatric population t(72) = 7,5, p<0.001. Male patients 
with DA also scored signifi cantly higher in comparison to the general population 
t(28) =  5,7, p<0.001 and signifi cantly lower in comparison with the psychiatric 
population t(28) = 2,8 p<0.001. 
Subsequently, Pearson’s correlation coeffi cients were calculated to analyse the 
correlations between the SGRQ and SCL-90 total score, FEV1%, W-max% and 
BMI. All correlations are displayed in table 3. Correlations between SCL-90 
and SGRQ and SCL-90 and BMI were both statistically signifi cant and clinically 
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relevant with small to medium effect sizes (r=0.47, r=0.23 respectively). In 
addition, the correlations between SGRQ and W-max% and SGRQ and BMI were 
both statistically signifi cant (p<0.01) and clinically relevant with medium effect 
sizes (r=0.34, r=-0.36 respectively). The correlation between W-max% and 
FEV1% was also statistically signifi cant (p<0.01) and clinically relevant with a 
medium effect size (r=0.38). As can be seen in table 3, SCL-90 scores were not 
signifi cantly correlated with W-max% and FEV1%. A multiple linear regression 
(dependent variable: SGRQ, independent variable SCL-90) revealed that all 
variables except for age and gender had a signifi cant association with SGRQ, 
together explaining 33% of all variance (table 4). 
Table 1. Characteristics of  patients with diffi cult asthma (N=102)
Characteristics N % Mean SD Range
Demographics      
Female 73 72
Age 47 15 18-79





Smoking history 45 44
Use of oral corticosteroids 24 24
Physiological measures
FEV1 % p 87 22 24-131
W-max % 71 23 14-128
Psychological measures
SCL-90* 171 56 92-372
SGRQ 62 17 20-92
Abreviations: BMI, Body Mass Index; FEV1%, forced expiratory volume in 1 second predicted; 
W-max%, maximal power output on cycle ergometer predicted; SCL-90, Symptom Checklist; SGRQ, 
Saint George Respiratory Questionnaire
*It should be remembered that scores in The Netherlands are not recoded to zero and scores range 
from 90 to 450.
Specifi cally, BMI, W-max% and SCL-90 were signifi cantly and independently 
associated with the SGRQ. Respectively, BMI explained 11%, FEV1% 8% and 
SCL-90 12% of total variance. The path model shows small effects of predictors 
on the SGRQ except for the SCL-90, which has a medium effect of 37% (fi gure 
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2). The direct effects of W-max% and BMI are about equal to their indirect 
effects. Both the SCL-90 (e=0,96) and the SGRQ (e=0,82) are explained mostly 
by outside variables.
Table 2. Mean SCL90* scores of 102 patients with diffi cult asthma receiving rehabilitation 
with mean SCL90 scores of the general population and psychiatric sample

















ANX 18,6 (7,6) 11 (4.3) 23-27 (9.5) 17,9 (8,5) 13 (5.7) 27-30 (10.2)
PH-ANX 10,4 (4,6) 7 (2.1) 11-13 (6.7) 11,6 (7,7) 7 (3.5) 12-15 (7.7)
DEP 32,3 (11,7) 18-20 (6.3) 37-43 (14.4) 31,4 (10,8) 21-22 (8.6) 44-50 (15.2)
SOM 28,1 (10,4) 15 (5.7) 24-27 (9.6) 28,0 (10,0) 16-18 (7.1) 26-30 (10.2)
IN 21,1 (7,4) 12 (4.6) 20-23 (7.9) 21,9 (6,9) 13-14 (5.1) 21-24 (8.5)
SEN 30,6 (13,4) 23-24 (6.8) 35-40 (14.7) 28,5 (10,1) 23-26 (8.8) 38-45 (16.0)
HOS 8,9 (3,2) 6 (2.5) 10 (5.1) 10,0 (4,1) 6 (2.4) 10-11 (5.5)
SLEEP 8,0 (3,9) 3 (2.4) 5-6 (3.6) 7,2 (3,7) 4 (2.8) 7-8 (3.8)







ANX, anxiety; PH-ANX, phobic anxiety; DEP, depression; SOM, somatization; IN, inadequacy of thought 
and action; SEN, interpersonal sensitivity and paranoid ideation; HOS, hostiligy; SLEEP, sleeping 
problems; Total PSY, general psychopathology.
*. It should be remembered that scores in The Netherlands are not recoded to zero and scores range 
from 90 to 450.
Table 3. Correlations between psychiatric symptoms, health status and physiological 
impairment (N=102)
 BMI FEV1% Wmax% SCL-90
BMI . . . .
FEV1 % -0,04 . . .
Wmax % -0,17 0,38** . .
SCL-90 0,23* 0,07 -0,19 .
SGRQ 0,34** -0,09 -0,36** 0,47**
* Correlation is signifi cant at p< 0.05 level
** Correlation is signifi cant at p < 0.01 level
Abbreviation: BMI= Body Mass Index, FEV1=Forced Expiratory Volume in one second, pred = predicted, 
Wmax= maximal output on cycle ergometer, 
SCL-90= Symptom Check List,  SGRQ= St. George’s Respyratory Questionnaire
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Table 4. Multiple linear regression analysis with patients’ perceived wellbeing (SGRQ) as 
the dependent variable
95% CI
Beta Low Upper p  
I   
Age 0,11 -3,87 14,00 0,26
Gender 0,06 -197,71 383,07 0,53
II
BMI 0,33 15,13 55,83 0,00*
III
FEV1 % pred 0,05 -4,39 7,25 0,63
W-max % pred -0,32 -15,04 -3,30 0,00*
IV
SCL-90 0,37 2,35 6,51 0,00*
Model I
    R square 0,02
    F Change 0,91
    Sig. F Change 0,41
Model II
    R square 0,13
    F Change 11,97
    Sig. F Change 0,00*
Model III
    R square 0,21
    F Change 5,02
    Sig. F Change 0,00*
Model IV
    R square 0,33
    F Change 17,90
    Sig. F Change    0,00*
* Independent variable is signifi cant at the 0.01 level (2-tailed)
Abreviations: BMI, Body Mass Index; FEV1, forced expiratory volume in 1 second; W-max, 
maximal power output on cycle ergometer; % pred, % predicted; SCL-90, Symptom Checklist; 
SGRQ, Saint George Respiratory Questionnaire
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This study demonstrates that patients with DA report high levels of psychiatric 
symptoms. The level of psychiatric symptoms is signifi cantly higher compared 
to the general population and approaches those of the psychiatric population. 
By comparing the level of psychiatric symptoms with the general and psychiatric 
population, this study provides an impression of the severity of psychiatric 
symptoms in these patients with severe DA. 
In our study, males and females reported no differences in psychiatric symptoms 
as well as perceived wellbeing. This is striking because in general, females tend 
to report higher levels of psychiatric symptoms in comparison to men [23]. 
And one would expect to fi nd a similar trend in the present sample especially 
since females with asthma tend to report more asthma symptoms and worse 
perceived wellbeing compared to male patients, despite having similar or better 
lung function [24]. Therefore in patients with DA, we should consider high levels 
of psychiatric symptoms, despite of gender. 
These patients with severe DA and high levels of psychiatric symptoms tend 
to report lower perceived wellbeing and tend to have higher BMI’s while 
age, gender, physical impairment and airway obstruction were not related to 
psychiatric symptoms or perceived wellbeing. This may be explained by the fact 
that the electively measured lung function does not capture the variability of the 
lung function, which is characteristic of asthma. 
Psychiatric symptoms were signifi cantly and independently related to perceived 
wellbeing. Our path model supported this relation. In particular, the level of 
psychiatric symptoms most strongly predicted perceived wellbeing in comparison 
to BMI and exercise performance. In this model, psychiatric symptoms hardly 
mediated the small effect of BMI and exercise performance on wellbeing. 
Considering these results, we could suggest that psychopathology has a larger 
infl uence on wellbeing in patients with DA than parameters like, age, gender, 
BMI, airway obstruction and exercise performance. Moreover, since perceived 
wellbeing is used to measure progress in rehabilitation [16], it appears especially 
important to specifi cally consider treating psychiatric symptoms in DA if one 
wants to improve wellbeing in DA. 
Our study has several limitations. First, variables like personality, traumatic 
experiences, Socioeconomic Status (SES) or other physical parameters were not 
corrected for in our model that could mediate the relation between psychiatric 
symptoms and perceived wellbeing. Another limitation is the fact that these 
fi ndings refer to severe DA patients and are not generalizable to the general 
population of asthma. Although we used a relatively large sample size, using a 
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sample from only one rehabilitation center further decreased generalizability. 
However, our population is similar to other populations with DA with regard to 
male/female ratio and SGRQ scores  [15], which makes our study exemplar for 
patients with DA.  Both severe somatic and psychiatric disorders that obviously 
needed treatment were excluded from rehabilitation. This further supports our 
fi ndings of high levels of psychiatric symptoms in DA.
This study is a fi rst start in the research on psychiatric symptoms in DA and 
does not allow for inferences about causality, i.e. whether psychiatric symptoms 
are a cause or consequence in DA. Therefore to obtain a clear understanding 
of this relation longitudinal research is recommended. In addition, research 
on the effect of treating psychiatric symptoms in DA on both the prevalence 
of psychiatric symptoms itself, on DA symptoms and the impact on perceived 
wellbeing is recommended. In addition, other possible mediating factors like 
personality, SES and other physical parameters should be considered in future 
studies. 
In conclusion our fi ndings reveal the importance of detecting psychiatric symptoms 
in patients with DA, independent of the severity of airway obstruction or of 
gender. Early referral to medical psychologists or psychiatrists is recommended. 
Our study gives an opportunity to improve the treatment of DA by further 
studying whether the treatment of these high levels of psychiatric symptoms 
indeed improve perceived wellbeing in patients with DA and thus lessen the 
burden of patients. 
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ABSTRACT
Background: Diffi cult asthma is a severe subgroup of asthma in which the 
main feature is uncontrollability of symptoms. Psychopathology is suggested to 
be prominent in patients with diffi cult asthma and considered important in its 
treatment; however, the evidence is scarce.
Aims: To describe psychopathology in diffi cult asthma, both major mental and 
personality disorders, based on diagnostic interviews.
Method: This study was conducted in a specialised asthma care centre. A total 
of 51 patients with diffi cult asthma were diagnosed at the start of the treatment 
programme using two structured clinical interviews for both major mental 
(SCID-I) and personality disorders (SCID-II) according to DSM-IV-TR.
Results: About 55% of the patients with diffi cult asthma had a psychiatric 
disorder of which 89% was undiagnosed and untreated before being interviewed. 
About 49% had a minimum of one major mental disorder of which the cluster 
of anxiety disorders was the most common cluster of major mental disorders, 
followed by somatoform disorders. About 20% were diagnosed with a personality 
disorder. Of the 10 patients with a personality disorder, 9 had an obsessive–
compulsive personality disorder.
Conclusions: This study demonstrates that more than half of patients with 
diffi cult asthma had a psychiatric disorder of which 89% was unrecognised. 
This study highlights the importance of offering patients with diffi cult asthma 
a psychiatric diagnostic interview and/or a psychiatric consultation as part 
of their routine medical examination and provision of appropriate psychiatric 
treatment. Moreover, it highlights the urgency of further research into the role 
of psychopathology in the development of diffi cult asthma.
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Asthma is a lifelong respiratory disease characterised by airway obstruction, 
airway infl ammation and bronchial hyperresponsiveness [1]. Asthma is a global 
health problem [1], which affects about 1 in 12 people in the USA (8% of 316 
million, 25 million) and numbers are increasing every year [2]. International 
guidelines on the treatment of asthma advocate a stepwise approach (Global 
Initiative for Asthma, GINA) [1]. This stepwise approach consists mainly 
of fi ve steps of pharmacological treatment, the fi nal step including systemic 
corticosteroids (apart from general recommendations of avoiding asthma 
triggers, adequate drug compliance, etc.). In most asthmatic patients, the 
occurrence of symptoms and/or asthma attacks can be controlled with the GINA 
approach. However, there is a subcategory of asthmatic patients who cannot 
control their symptoms despite treatment at step 4 or 5 of the GINA guidelines 
[1]. In clinical practice, these patients are defi ned as those who present with 
diffi cult asthma [3] affecting approximately 5% of the asthmatic population [4]. 
This would mean that about 1.25 million people in the USA and 2.5 million in 
Europe suffer from diffi cult asthma [1].
Diffi cult asthma has a profound impact on health status and quality of life [5]. 
Patients with diffi cult asthma have frequent exacerbations that can result in 
hospitalisations, emergency room visits [6, 7] and days of absence from work 
or school [8]. Moreover, patients with diffi cult asthma have an increased risk 
of sudden asthma death and adverse effects of high-dose corticosteroids [6]. 
Although the interest in diffi cult asthma has grown considerably, the aetiology 
of diffi cult asthma is poorly understood. It is well known that major mental 
disorders are highly prevalent (31%) in asthma patients in general [9] compared 
with the general population (26%) [10]. This 31%, however, encompassed both 
patients with treatable asthma and diffi cult asthma, which leaves the question 
whether the higher prevalence could be attributed to patients with asthma in 
general or to the diffi cult asthma population specifi cally. The prevalence of major 
mental disorders in diffi cult asthma appears to be high, but is hardly studied 
[11]. Two studies by Heaney et al. [11, 12] showed a prevalence of 49% in 
diffi cult asthma. However, these studies did not use structured interviews and 
used ICD-10 criteria instead of the DSM-IV-TR13 criteria for assessing mental 
and personality disorders. These studies did report 81.3% of mental disorders 
to be unrecognized [11]. Although there is a recent publication on personality 
traits in diffi cult asthma [14], to the best of our knowledge the prevalence 
of personality disorders in diffi cult asthma has not been previously reported 
utilising systematic research diagnostic interviews. 
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Therefore, the current study assessed the prevalence of psychopathology in 
diffi cult asthma focusing on both major mental and personality disorders using 
research diagnostic interviews according to the DSM-IV-TR [13].
METHOD
Setting
This study was conducted in Asthma Centre Heideheuvel, Hilversum, The 
Netherlands, a specialised asthma care centre that offers in-patient pulmonary 
rehabilitation. Asthmatic patients referred to in-patient rehabilitation have 
highly impaired health status and no satisfactory response to prior medical 
and nonmedical treatment by asthma specialists, often including outpatient 
rehabilitation [15, 16]. These complex patients with diffi cult asthma receive 
a comprehensive 3-month rehabilitation programme on an in-patient basis 
by an interdisciplinary team of healthcare professionals, including pulmonary 
physicians and specialised healthcare psychologists, as described in detail 
elsewhere [15, 16]. Patients enter the rehabilitation centre only after a 
multidisciplinary assessment of four days, confi rming their indication. Patients 
have to be abstinent from smoking during rehabilitation.
Participants
During a period of 17 months, 65 patients with diffi cult asthma entered the 
treatment programme and were invited to participate in the current study. This 
included, apart from the standard intake programme, a psychiatric interview. 
Seven patients did not give informed consent and another seven patients 
dropped out during the intake of the rehabilitation programme before diagnostic 
interviews were performed. The remaining 51 patients consented to participate. 
Their characteristics are shown in Table 1.
Measurements
In the fi rst weeks after the start of the programme, each patient was interviewed 
by trained psychologists with the structured clinical interview (SCID-I) [17] 
diagnosing major mental disorders and the structured clinical interview (SCID-
II) [18] diagnosing personality disorders, both according to DSM-IV-TR [13].
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Table 1. Characteristics of patients with DA (N=51)
Characteristics N Means ± S.D.
Sex, M/F 10/41





























SES = Socioeconomic Status; BMI = Body Mass Index; FEV1% = % predicted forced 
expiratory volume in 1 second; GINA = Global Initiative for Asthma
Ethical principles
Both the institutional medical ethics committee of the Asthma Centre and the 
medical ethics committee of the Utrecht Medical Centre approved the study 
protocol according to Dutch law. Patients were sent information about the study 
before they agreed on participation. All patients gave written informed consent.
Statistical methods
Statistical analysis was performed using SPSS Statistics for Windows Version 
19.0. To determine characteristics and psychopathology of the participants, 
descriptive statistics were used. Associations between subgroups of patients 
were analysed using chi-square statistics.
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RESULTS
The characteristics of the 51 patients with diffi cult asthma are shown in Table 
1. Of these, 41 patients (80.4%) were female, 45.1% were obese, 47.1% had 
a medium educational level and 84.3% middle-class SES. Of the 51 patients 
with diffi cult asthma, 28 patients (54.9%) had one or more major mental and/
or personality disorders (Table 2). 
Table 2. Major mental and personality disorders in 28 out of a sample of 51 Diffi cult 










Psychiatric disorders2 28 (54,9) 26 (63,4) 2 (20)
Major mental disorders 25 (49,0) 24 (58,5) 1 (10)
Mood disorders 12 (23,5) 12 (29,3) 1 (10)
Major depressive disorder 9 (17,6) 9 (22,0) 0
Dysthymic disorder 2 (3,9) 2 (4,9) 0
Bipolar disorder 1 (2,0) 1 (2,4) 0
Anxiety disorders 15 (29,4) 12 (29,3) 1 (10)
Social phobia 4 (7,8) 4 (9,8) 0
Specifi c phobia 5 (9,8) 4 (9,8) 1 (10)
PTSD 4 (7,8) 4 (9,8) 0
Panic disorder 1 (2,0) 1 (2,4) 0
OCD 1 (2,0) 1 (2,4) 0
Substance disorders 1 (2,0) 1 (2,4) 0
Substance abuse disorder 1 (2,0) 1 (2,4) 0
Somatoform disorders 12 (23,5) 11 (26,8) 1 (10)
Somatization disorder 5 (9,8) 5 (12,2) 0
Undifferentiated somatoform disorder 4 (7,8) 3 (7,3) 1 (10)
Pain disorder 3 (5,9) 3 (7,3) 0
Personality disorders 10 (19,6) 9 (22) 1 (10)
Borderline personality disorder 1 (2,0) 1 (2,4) 0
Avoidant personality disorder 3 (5,9) 3 (7,3) 0
Obsessive compulsive personality disorder 9 (17,6) 8 (19,5) 1 (10)
Dependent personality disorder 1 (2,0) 1 (2,4) 0
Personality disorder NOS 1 (2,0) 2 (4,9) 0
PTSD, Post traumatic stress disorder, OCD, obsessive compulsive disorder, NOS, not otherwise specifi ed
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Females were more likely to have a major mental disorder (58.5%) compared 
with male patients (10.0%; χ2=7.58, d.f.=1, P=0.006), which was not the case 
for personality disorders. As can be seen, 25 out of 51 patients (49.0%) had 
a major mental disorder, and 10 out of 51 patients (19.6%) had a personality 
disorder. Seven out of 51 patients (13.7%) reported both a major mental disorder 
and a personality disorder. Ten out of 51 patients (19.6%) reported more than 
one major mental disorder and 3 out of 51 patients (5.9%) reported more 
than one personality disorder. Overall, anxiety disorders (29.4%) were the most 
common cluster of disorders, followed by somatoform disorders (23.5%) and 
mood disorders (23.5%). Airway obstruction (FEV1%) did not differ between 
the patients with and without a psychiatric diagnosis (data not shown).
Of the 28 patients who were diagnosed with a psychiatric disorder, 3 patients 
had had a psychiatric diagnosis before referral to the rehabilitation centre: one 
had an obsessive–compulsive personality disorder (receiving psychotherapy), 
one had a somatization disorder (receiving psychotherapy) and one patient had 
a major depressive disorder (using antidepressants). This means that 25 of 
the 28 (89.3%) patients had a psychiatric diagnosis, which was not diagnosed 
before. Of the 23 patients who were not diagnosed with a psychiatric disorder 
according to the structured interviews, one patient received antidepressants 
and another six patients received benzodiazepines for sleeping problems (all 
prescribed by their GP).
DISCUSSION
This is one of the fi rst studies in patients with diffi cult asthma assessing 
psychopathology using the DSM-IV-TR criteria [19, 20]. The strength of the 
current study is the involvement of structured interviews (SCID-I and SCID-II) 
in order to get a DSM-IV-TR classifi cation. The current study showed that over 
half (54.9%) of the patients with diffi cult asthma referred to the specialized 
asthma care centre had one or more psychiatric disorders (89.3% of which 
were previously unrecognised). Specifi cally, 49% of all patients had a major 
mental disorder and 19.6% were diagnosed with a personality disorder. Heaney 
et al. [11, 12] reported a similar prevalence (49%) of major mental disorder 
in patients with diffi cult asthma of which 81.3% was unrecognised. However, 
this study did not use structured interviews and diagnosed according to ICD-10 
criteria. This prevalence is higher in comparison to the 31–34% reported by two 
studies by Lavoie et al. [9, 21] in asthmatic out-patients, encompassing both 
‘normal’ asthmatic patients and patients with diffi cult asthma. The prevalence of 
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49% of major mental disorder in the current study is also substantially higher in 
comparison to the prevalence in the general population in the USA (26.6%)10 
and in The Netherlands (18%) [22]. Similarly, the prevalence of personality 
disorders of 19.6% in the current study is also substantially higher compared 
with the general population in the USA (9%) [23] and in The Netherlands 
(13.5%)[24].
In the current study, the cluster of anxiety disorders was most common (29.4%) 
followed by somatoform disorders (23.5%) and mood disorders (23.5%), 
respectively. Specifi cally, major depressive disorder was the most common 
major mental disorder (17.6%) diagnosed and obsessive–compulsive personality 
disorder (17.6%) was the most commonly diagnosed personality disorder. 
The current study is among the fi rst using research-based standardised 
instruments based on DSM-IV-TR criteria to assess a wide range of DSM disorders 
including personality disorders in diffi cult asthma. Since we studied a group of 
patients with complex asthma in one specialised asthma care centre, the question 
remains open whether these fi ndings are generalizable to the total population 
of patients with diffi cult asthma. In the current study, all patients did have 
diffi cult asthma according to GINA guidelines. However, patients who smoked, 
patients without suffi cient learning ability for the (intensive) rehabilitation 
programme (e.g. because of intellectual disability, neuropsychological problems, 
motivational problems) and patients with known psychiatric or medical diseases 
interfering with this programme were excluded (as part of general policy of the 
rehabilitation centre) which might have resulted in an underestimation of the 
prevalence of psychiatric disorders. And the small number of male participants 
does not warrant a conclusion about differences between male and female 
patients with diffi cult asthma. 
About 89.3% of the patients with diffi cult asthma in the current study who 
received a psychiatric diagnosis were not diagnosed. Because of the dramatic 
manifestation of diffi cult asthma, psychiatric symptoms like anxiety or panic 
can be mistaken for asthma symptoms, which might explain the high number 
of unrecognised psychiatric disorders. Moreover, stigma about psychiatric 
disorders, for instance, resulting in being afraid that a psychiatric disorder would 
negatively impact asthma treatment, could cause unwillingness to acknowledge 
and accept psychiatric symptoms [25]. 
Although beyond the scope of the current study, an important question 
about the direction of the relation is: is psychopathology a contributor or a 
consequence of diffi cult asthma? Psychiatric symptoms could worsen asthma 
symptoms and the dramatic manifestation of asthma symptoms in diffi cult 
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asthma could probably cause or worsen psychiatric symptoms. However, the 
impact of psychiatric symptoms on diffi cult asthma does not appear to be a 
straightforward one [11]. Moreover, because by defi nition, most patients with 
diffi cult asthma use corticosteroids and it is well known that these drugs have 
major psychotropic side-effects, a possible independent effect of this medication 
on major mental disorders should be taken into account [26]. Psychological 
distress is heightened in patients with severe prednisone dependent [14] and 
the use of oral corticosteroids are related to lower quality of life [27]. Several 
psychiatric disorders are signifi cantly associated with adult-onset asthma 
[28]. Prospective research is needed in which patients who develop diffi cult 
asthma after a prior diagnosis of asthma are followed and for patients with a 
fi rst diagnosis of a psychiatric disorder and with a fi rst diagnosis of asthma, 
to elucidate on a possible contributing role of psychiatric disorder in diffi cult 
asthma.
Both major mental disorders and personality disorders [29] have a substantial 
impact on quality of life, which is known to be poor in patients with diffi cult 
asthma [30]. Based on the effect of psychiatric therapy in general [31], it is 
reasonable to suggest that the treatment of major mental and personality 
disorders also improves quality of life in diffi cult asthma. In chronic obstructive 
pulmonary disease (COPD), a severe pulmonary disease in which also high 
doses of corticosteroids are used, comparable fi gures of psychiatric disorder are 
reported [32]. In this population, the risk of missing diagnoses and treatment 
of concurrent psychiatric disorder is also high [32]. Studies on the treatment 
of psychiatric disorder in COPD show improvement for both physical and 
psychiatric complaints [32]. Given these results, one might hypothesise that 
similar outcomes of treatment might be obtained in a diffi cult asthma population. 
Future research is needed to determine the benefi t of psychotherapy and/or 
pharmacotherapy in standard diffi cult asthma treatment.
This study advocates the importance of offering patients with diffi cult asthma 
a psychiatric diagnostic interview and/or a psychiatric consultation as part of 
their general medical examination since 54.9% of patients with diffi cult asthma 
were diagnosed with a psychiatric disorder, most of them unrecognised and 
untreated. Furthermore, the results stress the urgency of further research into 
the potential roles of mental disorders in diffi cult asthma and of diffi cult asthma 
in mental disorders.
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ABSTRACT
Objective: Alexithymia is considered a complicating factor of asthma. Patients 
with alexithymia do not adequately perceive emotions and bodily sensations 
as is necessary in asthma in order to be able to control asthma symptoms. 
This can lead to non-optimal asthma management and low quality of life. We 
reviewed the available literature on empirical fi ndings regarding the prevalence, 
relation with severity of asthma, asthma control, quality of life and treatment of 
alexithymia in asthma.  
Methods: Studies in English language journals using MEDLINE were retrieved 
by an electronic search published from 1990 till July 2015. 
Results: The search identifi ed 11 empirical studies. The results showed that 
the prevalence of alexithymia in asthma was high and alexithymia was related 
to more severe levels of asthma symptoms, worse asthma control and lower 
quality of life. No studies regarding treatment of alexithymia in asthma were 
found.
Conclusions: The prevalence of alexithymia in asthma is high and it is related 
to the severity of asthma, worse asthma control and lower quality of life. Future 
research should focus on the role of alexithymia in asthma and specifi cally if 
treatment of alexithymia in asthma improves outcome. 
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Asthma is a highly prevalent respiratory disease [1]. Its incidence is rising, 
becoming a growing health problem in society [1]. Asthma is in general a well 
treatable chronic disease. Treatment is fi rst aimed at keeping the airways in the 
best possible state and is, secondly, aimed at gaining control over the disease, 
hence maximizing symptom free periods [2-3]. Optimal control over asthma 
results in minimal or absent impact of the disease on quality of life [4]. Severity 
of asthma is classifi ed based on responsiveness to treatment [2,5] e.g. the level 
of control over asthma (severity based on GINA criteria [2]). Not all patients 
achieve optimal control over asthma symptoms, which can lead to frequent 
exacerbations and hospitalizations [6-8] and hence low quality of life. Diffi cult 
asthma (DA) is a severe kind of asthma in which patients cannot control the 
manifestation of the disease despite being maximally treated [7-8]. 
Alexithymia, as one of the patient related factors, is associated with insuffi cient 
disease control in asthma [9]. Literally alexithymia means without words 
for emotions [10]. It consists of four aspects: (1) diffi culty identifying and 
describing feelings; (2) diffi culty distinguishing feelings from bodily sensations; 
(3) reduction or absence of symbolic thinking; (4) utilitarian thinking without 
fantasy [11]. Alexithymia is a dimensional concept that can be present from 
low negligible levels to high pathological levels [12]. It is strongly related to 
concepts as psychological mindedness [13], emotional intelligence [14] and 
mentalization [15].
Alexithymia is considered a risk factor for both psychiatric and somatic diseases 
that are infl uenced by disordered affect regulation [16]. For asthma patients 
adequate perception of bodily sensations is essential to 1) describe asthma 
symptoms toward their doctors so they can treat them accordingly 2) seek help/
treatment if necessary 3) take medication when necessary [17]. Patients with 
asthma need to be able to adequately perceive bodily sensations [17]. However, 
patients with alexithymia specifi cally have an impaired ability to create mental 
representations of emotions, which is necessary to be able to distinguish between 
feelings and bodily sensations; as a consequence alexithymia can be regarded 
as an impairment that may lead to the misinterpretation / misperception of 
physical symptoms [4, 18-20]. At one hand, alexithymia tends to infl uence illness 
perception resulting in over reporting and catastrophizing of somatic sensations 
and symptoms resulting in poor illness behaviour [4,21]. On the other hand, 
underestimation of both physical and emotional sensations and interpretation 
of symptoms may result in non-optimal medication use, more exacerbations, 
hospitalisations and therefore worse control over asthma symptoms and low 
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quality of life [4,21]. Alexithymia can be seen as a complicating factor in 
the development and sustainment of uncontrolled (diffi cult) asthma or as a 
consequence of the overwhelming nature of severe asthma symptoms [21]. 
Empirical evidence of alexithymia as a patient related factor in asthma appears 
to be scarce [22]. Alexithymia research in asthma started in 1980 by Kleiger et 
al. 23-24] and was followed by several studies [25-27]. Asthma was considered 
a psychosomatic disease and alexithymia as associated with the development 
of asthma [28]. However, research showed little evidence indicating that 
alexithymia is associated with the development of asthma. The focus of research 
changed into alexithymia as a complicating factor in asthma, resulting into a 
new area of research. 
Since alexithymia is nowadays considered in literature as an important 
complicating factor in both asthma and diffi cult asthma, a literature review that 
critically investigates the studies that reported on a possible relation between 
asthma and alexithymia is necessary. To the best of our knowledge, such a 
review has not yet been published.
The aim of the present study is to systematically review current literature with 
regard to (1) the prevalence of alexithymia in asthma; (2) possible associations 
between alexithymia and severity of asthma, asthma control and quality of life; 
(3) treatment and treatment outcome of alexithymia in asthma.
METHOD
A comprehensive literature search of the MEDLINE database on literature 
published from 1990 till July 2015 was conducted on alexithymia in asthma. The 
search was conducted by pairing the key words ‘asthma’ and ‘alexithymia’. All 
fi elds were selected for a thorough search. 
Studies meeting the following criteria were included in this review: (a) participants 
were adults above 18 years, (b) alexithymia was studied directly related to asthma, 
e.g. prevalence, a relation with severity of asthma, asthma control, quality of life 
or treatment of alexithymia in asthma (c) statistical analyses were well described 
and effect sizes could be calculated, (d) studies were published in English.
Once an initial pool of articles was obtained, titles were screened on inclusion 
criteria. Abstracts from retained records were assessed to identify potentially 
relevant articles and duplicates were removed. For the remaining records full 
texts were obtained and articles were added to the search by cross-referencing 
of full texts. All eligible papers were submitted to close reading and were coded 
by two readers (L.P. and A.P.) on the following characteristics: (a) number of 
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participants, (b) asthma diagnosis of participants, (c) statistical analysis, (e) 
main fi ndings concerning alexithymia, (f) control group, (g) prevalence, (h) 
severity, (i) quality of life. Effect sizes were calculated according to the analysis 
used, i.e. r for paired qualitative data, f2 for ANOVA or multiple regression and phi 
for chi squared tests [29, 30]. According to Cohen’s r criterion [30] correlations 
of r ≥ 0.10 correspond with small, r ≥ 0.30 with medium and r > 0.50 with large 
effect-sizes, the latter two are considered clinically relevant. Cohen’s f2 of f2 ≥ 
0.02 corresponds with small, f2 ≥ 0.15 with medium and f2 > 0.35 with large 
effect-sizes. Phi of ≥ 0.1 corresponds with small, phi ≥ 0.3 with medium and 
phi > 0.5 with large effect-sizes. The results of the search are summarized in 
table 1. 
RESULTS
 The search initially identifi ed 71 hits. After applying the inclusion criteria 
mentioned above, the search resulted in 11 articles. There were no papers found 
by cross-referencing. The studies are described in table 1. Five of 11 articles 
used a control group, i.e. asthma and non asthmatic patients, students with 
asthma and students with who recently experienced an asthma attack, three 
studies of NFA and asthma patients of which one study also with a non asthmatic 
control group. The prevalence of alexithymia reported in the literature highly 
varied (table 1). From 0 to 19% in asthma patients compared to 24-36% in 
NFA patients. The two studies with the lowest prevalence had very low sample 
sizes: n = 44 (NFA), n = 40 (asthmatic control group) [34] and n = 25 [36]. 
Prevalence of alexithymia in asthma was higher compared to healthy controls 
and higher in patients with NFA compared to patients with asthma without NFA 
[32, 38-39]. 
Nine of 11 studies reported on a possible relation between alexithymia and severity 
in asthma. Seven out of these nine studies reported a signifi cant positive relation 
between alexithymia and severity in asthma with large effect sizes. Two studies 
[33,36] reported no relation between alexithymia and severity in asthma, both 
with small effect sizes in contrast to the other seven studies. Two of 11 studies 
reported a relation between alexithymia and worse asthma control [33,36] (with 
respectively phi = 0.04 and r = 0.57 effect sizes) while one study found no 
relation [37] with asthma control (effect size not mentioned). Four of the 11 
studies reported that alexithymia was related to poor quality of life [33, 35-37]. 
There were no studies on the possible effects of treatment of alexithymia in 
asthma. 
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DISCUSSION
The current review shows a prevalence of alexithymia in asthma between 14,7% 
and 36% (table 1). This is high compared to the general population (13%) [41]. 
The study of Martinez et al. [32] confi rmed that there is more alexithymia in 
asthma compared to control subjects without asthma. Moreover, the highest 
percentages of 24% [38] and 36% [39] are reported in NFA patients and the 
percentage of alexithymia is higher in NFA patients compared to asthma controls 
[38,39].  These results suggest that alexithymia is related to asthma in general 
and specifi cally to more severe asthma symptoms. Only two studies out of nine 
did not confi rm this relationship, but these studies lacked suffi cient power. There 
was also a relation between alexithymia and worse asthma control and lower 
quality of life. 
The suggestion that alexithymia is a patient related factor in asthma is 
confi rmed by the results of our review. Treatment of alexithymia in asthma 
could therefore be an opportunity in the management of asthma, especially for 
patients with more severe asthma like diffi cult asthma. However, no studies 
on the treatment of alexithymia in asthma are reported yet. Research on 
alexithymia in patients with other somatic diseases like coronary heart disease 
may give new possibilities on the treatment of asthma [42]. For instance, in 
coronary heart disease, group therapy reduces alexithymia for over two years. 
More importantly, patients with reduced alexithymia scores have better somatic 
outcomes that last over two years [42].  Several pathways are suggested in 
which the treatment of alexithymia can alter the prognosis of somatic disease 
[22]. When patients with alexithymia learn to give words to their feelings, 
learn how to discriminate between feelings and bodily sensations and move 
their attention more toward their inner experience, the cognitive processing 
of their feelings improves. This reduces prolonged states of emotional arousal 
[16], tonic physiological hyperarousal, unhealthy behaviour, biased perception 
and reporting of bodily sensations [22]. It therefore improves cardiovascular 
management and also reduces health care use [22]. There is no reason to 
suggest that these mechanisms will not work in (diffi cult) asthma patients. 
Although psychotherapy is proven effective in treating alexithymia, as far as we 
know no treatment specifi cally designed to treat alexithymia in chronic conditions 
has been designed yet [13]. The importance of treating psychological symptoms 
is becoming more evident [2]. Specifi c psychotherapeutic interventions targeting 
alexithymia could possibly also be incorporated in pulmonary rehabilitation and 
thereby possibly further improve health outcome. 
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The strength of this paper is that we critically analysed all papers and calculated 
the effect sizes of the studies. This makes it easier to make cross study 
comparisons and it makes these conclusions more reliable. However, it should 
be mentioned that this systematic review only revealed 11 studies. 
CONCLUSION
Alexithymia is highly prevalent in asthma and is related to severity of asthma 
symptoms, worse asthma control and lower quality of life. Treatment of 
alexithymia in patients with both asthma and high levels of alexithymia could 
be promising, however no empirical outcome-studies are available. More 
research is necessary on the role of alexithymia in asthma, the development of 
psychotherapeutic interventions in patients with both asthma and alexithymia 
and on outcome of such therapies. 
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ABSTRACT
Introduction: Diffi cult asthma is a serious condition in which asthma symptoms 
are not responsive to standard treatment, which is possibly complicated by 
psychological symptoms. The (longterm) benefi t of specialized pulmonary 
rehabilitation (PR) adjusted for the level of psychological symptoms at baseline, 
has not yet been studied in patients with diffi cult asthma.  
Aims: (1) to evaluate if health related wellbeing and the level of psychological 
symptoms of patients with DA change during PR (2) to assess if there is an 
association between psychological symptoms and the effect of PR on health 
related wellbeing (3) to evaluate whether a possible benefi t of PR persists at 
longitudinal follow-up. 
Methods: 121 patients with diffi cult asthma participated in an inpatient PR 
programme for 12 weeks; At baseline (T0) and at discharge (T1), health related 
wellbeing (SGRQ) and psychological symptoms (SCL-90) were assessed. Health 
related wellbeing was also measured at three (T2), six (T3), 12 (T4) and 18 (T5) 
month’s post-rehabilitation.
Results: After PR there were signifi cantly lower SGRQ scores (t(116)=13,21, 
p<.000, d=1,22) and signifi cantly lower SCL-90 total scores (t(116=6,89, 
p<.000, d=0,64). Adjusted for SCL-90 scores at baseline, SGRQ scores were 
still signifi cantly lower compared to baseline scores at discharge, 3, 6, and 12 
months follow up  (F(185, 220)=2,14, p=.0024).
Conclusions: PR in DA patients results in signifi cant short- and long-term 
improvement in health related wellbeing, also in DA patients with high levels of 
psychological symptoms. 
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Patients with diffi cult asthma (DA) are severely impaired by the uncontrollable 
and invalidating nature of their asthma symptoms [1]. Although patients with DA 
represent a minority of the total asthma population, about 1.25 million people 
in the US and 2.5 million in Europe suffer from DA [2]. Patients with DA do not 
reach an acceptable level of control at step 4 or 5 of prescribed treatment [3]. 
The impact on health care is substantial, because of the many hospitalizations, 
emergency room (ER) visits and high medication use [3-6]. Standard treatment 
for patients with asthma - prescription of medication, avoiding asthma triggers 
and improving self-management strategies- is directed at maximizing symptom 
free periods and keeping the airways in the best possible physical state [2, 
3]. DA is a condition in which symptoms are not responsive to this standard 
treatment [2, 7]. Specialized pulmonary rehabilitation (PR), an intensive 
rehabilitation programme of several weeks or months, is offered to patients 
with severe asthma including DA patients when pulmonary rehabilitation 
in the general hospital setting does not yield suffi cient progress. PR is an 
intensive interdisciplinary treatment consisting of a combination of physical and 
psychological interventions. PR has been shown to be effective in improving 
health related wellbeing in severe asthma [8]. However evidence of benefi ts of 
PR specifi cally in DA patients, is scarce since outcome studies on PR are often 
focused on patients with severe asthma (including DA patients) and sometimes 
including COPD patients as well. To the best of our knowledge, no studies have 
been reported on treatment outcome for adult patients with DA specifi cally. 
Moreover, of the few studies that reported treatment outcome in severe asthma 
most focussed on the possible benefi t immediately post-treatment, e.g. when 
patients are discharged from the PR programme rather than longitudinal 
outcome [9]. 
DA patients are at high risk for co-morbid psychological symptoms, including 
severe psychiatric disorders [10]. In an earlier study we found that over half of 
patients with DA had a psychiatric disorder [10]. Psychological symptoms are 
generally regarded as a complicating factor in the treatment of asthma [2]. The 
possible impact of co-morbid psychological symptoms on a possible benefi t of 
PR for patients with DA has never been reported.  
Therefore, the primary aim of the present study was to evaluate if health related 
wellbeing and the level of psychological symptoms of patients with DA change 
during PR and if patients may benefi t from an intensive PR programme.  The 
second aim was to assess if there is an association between psychological 
symptoms and (lack of) benefi t of PR on health related wellbeing. The third aim 
was to evaluate whether a possible benefi t of PR persists at longitudinal follow-up.
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This prospective study was conducted in ‘Revant Centre for Pulmonary 
Rehabilitation’, Breda, The Netherlands; a specialised tertiary asthma care 
centre that offers both inpatient and outpatient pulmonary rehabilitation. 
The rehabilitation itself consists of a comprehensive 3-months rehabilitation 
programme by an interdisciplinary team of healthcare professionals, including 
pulmonologists, physiotherapists, social workers and specialised health care 
psychologists [11]. Patients enter the PR after following a multidisciplinary 
assessment of four days. Patients have to be abstinent from smoking if they 
want to participate in the rehabilitation programme. Details of the PR of this 
institute have been described elsewhere [11].
Participants and procedure
From October 2006 until December 2013, 121 patients with DA were included 
in the specialised PR programme (T0).  Treatment outcome was evaluated at 
discharge (T1), three months post PR (T2), six months post PR (T3), 12 months 
post PR (T4) and 18 months post PR (T5). Of these 121 patients (T0), 3% 
dropped out during the programme (i.e. did not complete PR). Therefore data 
analysis refers to 116 patients who ended the PR (T1); of these, 34 were lost to 
follow-up at 3 months (T2), 4 at six months (T3), 20 at 12 months (T4) and 7 
at 18 months (T5) (table 1). 
Measurements
Health related wellbeing (dependent variable) was assessed at T0, T1, T2, T3, 
T4 and T5 and was measured with the Saint George Respiratory Questionnaire 
(SGRQ), a commonly used 76 item questionnaire with three sub-domains, 
e.g. symptoms, activity and impact [12]. A summary score is calculated by 
empirically weighted item scores. Scores range from 0 (no impairment) to 100 
(maximal impairment), thus higher scores refl ecting poorer health status. A 
change of four points in summary score after PR is regarded a slightly effi cacious 
change, eight points as a moderate change and 12 points as a very effi cacious 
change. The SGRQ has proven to be a valid and reliable instrument [12] and 
was assessed at T0, T1, T2, T3, T4 and T5. 
Psychological symptoms (independent variable) were measured at baseline 
(T0) and at discharge (T1) with the Symptom Checklist (SCL90) of Derogatis 
[13], a 90-item multi-dimensional self-report symptom inventory that measures 
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different symptoms of psychopathology. Total scores are used for the indication 
of psychological symptoms. 
Physiological impairment was measured at T0 by airway obstruction: (FEV1, 
Forced Expiratory Volume in One Second) and after taking the deepest breath 
possible (FVC, Forced Vital Capacity), which is called FEV1%, and exercise 
performance was measured by the maximal power output on a cycle ergometer 
(W-max%) that has both good reliability and validity [14].
In addition, demographics and BMI were assessed at T0.  
Ethical Principles
This study was review board exempt since all assessments are part of usual care 
provided by the rehabilitation centre and all data were anonymized.  Patient’s 
informed consent was obtained for the utilization of the data for research 
purposes.
Statistical Methods
All statistical analyses were performed with the IBM SPSS Statistics for Windows 
Version 22.0 [15]. 
Differences between patients who dropped out at different times of follow-
up were analysed using independent samples t-tests for categorical variables 
and chi-square tests for dichotomous variables. Correlations between SGRQ 
baseline (T0) and SCL-90 sum-scores (T0), SGRQ after discharge (T1), SCL-
90 after discharge (T1), the change (delta) between SGRQ T0 and T1 were 
evaluated using Pearson correlation (P < 0.01, two-tailed). Clinical relevance of 
the correlation was determined using Cohen’s criterion [16]. According to this 
criterion correlations of r ≥ 0.10 correspond with small, r > 0.30 with medium 
and r > 0.50 with large effect-sizes, the latter two are considered clinically 
relevant [16].
Possible changes of health status during the PR (T0-T1) were analysed using 
paired samples t-tests. Similarly, possible changes of psychological wellbeing 
(SCL-90 sum scores) during PR (T0-T1) were analysed using paired sample 
t-tests. Data are mean ± standard deviation and signifi cance level, unless 
otherwise stated. Clinical relevance for effect sizes was determined using Cohen’s 
d criterion [17]. According to this criterion correlations of d ≥ 0.20 correspond 
with small, d > 0.50 with medium and d > 0.80 with large effect-sizes, the latter 
two are considered clinically relevant [17].
In order to evaluate the possible benefi t during PR (T0 -T1), specifi cally if baseline 
SCL-90 scores were associated with the amount of change in SGRQ scores, 
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a stepwise multiple linear regression analysis was performed with difference 
of SGRQ summary scores between T1 and T0 as dependent variable and the 
T0 SCL-90 scores as independent variable [18], entered into the regression as 
fi rst block. We adjusted for several parameters (age, gender, BMI, W-max%, 
FEV1%), which were entered as separate blocks, i.e. the second block age and 
gender, third BMI, fourth W-max and FEV1%. The adjusted R-square statistic was 
determined to indicate the proportion of explained variance, and the F-change 
statistic was determined to indicate the signifi cance of adding separate blocks. 
Clinical relevance for R-square statistic was determined using Cohen’s criterion 
[16]. According to this criterion a R2 ≥ 0.010 correspond with small, R2 > 0.059 
with medium and R2 > 0.138 with large effect-sizes. 
Finally, the possible longitudinal benefi t of PR on health related health status 
(SGRQ summary scores) was evaluated using repeated measurements (GLM-
ANOVA) with SGRQ scores at T0, T1, T2, T3, T4 and T5 as within-subjects factor 
[18] and SCL-90 baseline scores as between-subjects factor with Bonferroni 
correction for multiple testing. Because of high rates of drop-out which are not 
incorporated in repeated measures analyses (GLM-ANOVA), the analysis was 
repeated with ‘linear mixed effect models’, also with a Bonferroni correction 
for multiple testing. This analysis, which is interpreted as linear regression 
analyses, has the advantage that its statistical analysis includes all available 
data, and does not include listwise deletion. 
RESULTS
The characteristics of patients with DA are shown in Table 1 at fi ve intervals 
(T0-T5). 
There were no signifi cant differences for age, gender, BMI, FEV1%, W-max%, 
SCL-90 scores at baseline (T0), SCL-90 scores at discharge (T1) and SGRQ scores 
at all intervals (T0-T5) between patients who dropped out and who did not drop 
out during PR or during follow-up (T0-T5) as is shown in Table 1. The mean sum 
SGRQ and SCL-90 scores at baseline (T0) were 62,8 (SD: 16,5) and 168,9 (SD: 
50,3), respectively. Correlations were signifi cant with large effect sizes between 
SCL-90 scores at baseline (T0) and SCL-90 scores at discharge (T1) (r=0,64), 
between SGRQ at baseline (T0) and SGRQ at discharge (T1)(r=0,51) (Table 
2). Correlations were signifi cant with medium effect size between the SCL-90 
at baseline and SGRQ at discharge (r=0,45), SGRQ at baseline (r=0,35) and 
SCL-90 at discharge (T1), SGRQ at discharge (T1) and SCL-90 at discharge (T1) 
(r=0,41). The correlation between SCL-90 baseline (T0) and SGRQ at discharge 
(T1) was signifi cant with a small effect size (r=0,27).
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At discharge (T1 versus T0), patients reported signifi cantly lower SGRQ scores 
(mean 21,34 sd ± 1,62, t(116) = 13,21, p<.0001, d = 1,22, large effect size) as 
well as  lower SCL-90 sum scores (mean 25,8 sd ± 3,7, t(116) = 6,89, p<.0005, 
d = 0,64, medium effect size, paired T-tests). 
Comparing the decrease of SGRQ scores during PR (T0 and T1, dependent 
variable: SGRQ delta scores, independent variable: SCL-90 sum scores at T0) 
a multiple linear regression analysis showed no effect for SCL-90 sum scores at 
baseline, after adjustment for age, gender, BMI, W-max% and FEV1% (table 3). 
There was an independent effect of BMI at T0 on the SGRQ delta scores. Higher 
BMI was signifi cantly associated with a larger decrease of SGRQ scores (R2 
0,09; p=0,04, medium effect size). Adding W-max% and FEV1% to the model 
increased the explained variance to 0.11 (R2 0,11; p=0,04, medium to large 
effect size). SCL-90 sum scores at baseline did not contribute to the decrease 
of SGRQ scores. 
In fi gure 1, the benefi t during follow-up is shown of SGRQ scores using GLM-
ANOVA with SCL-90 baseline (T0) as between subject factor. As can be seen, 
the SGRQ scores decreased signifi cantly over time (F(5,20)=42,46, p<.0005, 
partial η2=0,91, fi gure 1). Adjusted for SCL-90, SGRQ scores still decreased 
signifi cantly over time (F(185, 20)=2,14, p<.0024, partial η2=0,95). Between 
baseline (T0) and SGRQ scores at discharge (T1) there was a decrease of 23,1 
points, which is a clinically relevant change [122. At follow up, at three months 
(T2), six months (T3), 12 months (T4) and 18 months (T5) there was a slight 
increase of the SGRQ sum scores but at 18 months follow-up the difference 
between T4 and T0 was still 15,9 points on the SGRQ, which is a signifi cant and 
clinically relevant change [12]. T5 and T0 was still 15,4 points, which is not a 
signifi cant (p=0.62) but still a clinically relevant change. Post hoc analyses with 
a Bonferroni adjustment revealed that SGRQ sum scores signifi cantly decreased 
from T0 to T1 (p=0.002), T2 (p=0.004), T3 (p=0.005), and T4 (p=0.027). 
SGRQ decreased from T0 to T5 however this was not signifi cant (p=0.088). The 
slight increase from T2 to T5 was not signifi cant. The drop out rate from T0 to 
T5 was over 50%, which is not incorporated in repeated measures analyses. 
We therefore repeated the analysis with a linear mixed effect model. This 
analysis showed the same effects, which makes it reliable to report the repeated 
measures analyses. The SCL-90 scores at baseline did not signifi cantly predict 
the change of SGRQ scores. 
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Figure 1. SGRQ mean scores and repeated measures for DA patients from baseline to 18 
months post PR
Table 2. Correlations between psychological symptoms, health related wellbeing at 
baseline, at discharge and between baseline and discharge (N=116)
 SCL-90 T0 SCL-90 T1 SGRQ T0 SGRQ T1
SCL-90 T0 . . . .
SCL-90 T1 0,64* . . .
SGRQ T0 0,45* 0,35* . .
SGRQ T1 0,27* 0,41* 0,51* .
SGRQ delta 0,11 -0,12 0,39* -0,59*
* Correlation is signifi cant at p< 0.01 level, two tailed
Abbreviation: SCL-90, Symptom Check List;  SGRQ, St. George’s Respiratory Questionnaire; T0, 
baseline; T1, at discharge; delta, the difference between T0 and T1
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Table 3. Stepwise multiple linear regression analysis with the delta of patients’ perceived 
wellbeing (SGRQ) as the dependent variable and baseline SCL-90 scores as independent 
variable, adjusted for age, gender, BMI, FEV1% and Wmax% (N=116)
95% CI







I   0,01 0,00 1,51 0,22
SCL-90 baseline 0,11 -0,03 0,11 0,22
II 0,03 0,00 1,14 0,33
SCL-90 baseline 0,12 -0,02 0,11 0,21
age -0,14 -0,39 0,06 0,14
gender 0,03 -5,80 8,46 0,71
III 0,09 0,05 6,68 0,01*
SCL-90 baseline 0,06 -0,05 0,09 0,55
Age -0,17 -0,43 0,01 0,07
Gender 0,00 -6,77 7,25 0,95
BMI 0,25 0,16 1,18 0,01*
IV 0,11 0,06 1,49 0,23
SCL-90 baseline 0,07 -0,04 0,09 0,49
age -0,16 -0,41 0,03 0,09
gender 0,04 -5,59 8,89 0,65
BMI 0,25 0,15 1,20 0,01*
FEV1% 0,13 -0,06 0,25 0,24
W-max% 0,06 -0,13 0,21 0,63
* Independent variable is signifi cant at the 0.05 level (2-tailed)
Abreviations: BMI, Body Mass Index; FEV1%, forced expiratory volume in 1 second predicted; SCL-90, 
Symptom Checklist; 
SGRQ, Saint George Respiratory Questionnaire; W-max%, maximal power output on cycle ergometer 
predicted;
DISCUSSION
The primary outcome of this study was that both health related wellbeing and 
psychological symptoms improve signifi cantly with a clinically relevant effect 
size in patients with DA during PR. Second, in contrast to what was expected, 
the level of psychological symptoms at baseline was not related to the progress 
made on health related wellbeing during PR. The third outcome was that the 
benefi cial effect of PR persisted over 12 months post PR. 
Patients were highly impaired at the start of rehabilitation, which is represented 
in very low health related wellbeing (high SGRQ scores), which is even lower 
compared to patients with severe asthma with frequent exacerbations [19]. 
Similarly, the level of psychological symptoms was very high, approaching norm 
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scores of the outpatient psychiatric population in The Netherlands [13]. Although 
patients had high levels of psychological symptoms and psychological symptoms 
are seen as complicating factors in the treatment of DA [7], these patients did 
benefi t from an intensive multidisciplinary specialized PR programme. The most 
likely explanation is that since there was a signifi cant amount of psychological 
interventions in the specialized PR programme, psychological symptoms were 
treated well enough not to intervene with the “physical elements” of the PR 
programme, making this programme suitable for patients with DA. This could 
also explain the improvement in psychological symptoms during PR. Therefore 
we conclude that the severity of psychological symptoms does not have to be 
a contra-indication for PR and does not require treatment before PR starts. 
However, because DA patients with severe psychiatric disorders were excluded 
from this study, it is diffi cult to generalize these fi ndings to all DA patients. 
This study has both its strengths and limitations. One of the strengths of our 
study is the measurement of not only short term but also long term benefi ts 
of PR in a group of DA patients (refl ecting a sub-group of asthma patients with 
very severe symptoms diffi cult to treat), which are often excluded from studies. 
It was also a relatively large population of well-defi ned DA patients. Although 
the drop-out rates were high during the follow-up of 12 months, the extra mixed 
models analysis which confi rmed the repeated measures analysis, made our 
results at follow up more reliable. A limitation of the study was that patients 
were only followed on health related wellbeing after discharge. For example data 
of hospitalisations, exacerbations, possible death, use of medication, the level of 
psychological symptoms during follow-up were unknown. In addition, pulmonary 
function and exercise performance was only part of our analyses at baseline 
with no data after discharge [2]. Therefore we could not adjust for physiological 
improvement during and after PR, which also might infl uence psychological 
and health related wellbeing. Also, psychological interventions during PR were 
individualized for each patient making it impossible to correct for the quality and 
quantity of psychological interventions during PR. In addition, data on possible 
additional physical and psychological interventions during follow up were not 
available. Since PR occurs in a highly specialized setting treating severely ill 
patients, a control group or RCT for obvious reasons was not possible.
CONCLUSION
PR may be considered as a benefi cial programme with long-lasting effect to 
increase health related wellbeing of DA patients, even in cases with high levels 
of psychological symptoms before treatment. 
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SUMMARY OF MAIN FINDINGS
Although asthma is a well treatable chronic disease, about 5% of patients 
does not respond well to regular (pharmacological) treatment and suffers 
from diffi cult asthma (DA) [1]. These patients are seriously restricted in their 
daily activities, consume a signifi cant part of medical assistance, suffer from 
frequent exacerbations, are prone to medical complications [2-4], and have 
low quality of life [5]. DA constitutes a relatively heavy burden on society [6]. 
Factors causing DA are not well understood. There are indications that – apart 
from pathophysiological factors—psychological factors may play a role in the 
development and maintenance of DA.  Although the widely accepted existing 
recommendations for treating general asthma following GINA criteria also 
incorporate a psychological attitude, empirical support for this line of reasoning 
seems scarce.
The main aim of this thesis was to gain a better understanding of DA from a 
psychological point of view. Specifi cally two concepts were studied in relation 
to DA, i.e. psychiatric symptomatology /syndromes and alexithymia. These two 
concepts are considered complicating factors in both worldwide management 
guidelines and clinical practice of DA.
A PSYCHOLOGICAL APPROACH IN UNDERSTANDING 
DIFFICULT ASTHMA
Psychopathology
Several available empirical studies confi rmed that there was a higher prevalence 
of psychiatric symptoms and syndromes in DA compared to the general 
population, as is described in Chapter 2. Moreover patients with DA and co-
morbid psychiatric symptoms experienced more asthma hospitalizations and 
exacerbations compared to patients with DA with less psychiatric symptoms 
[7]. Literature suggested a possible role of psychiatric symptomatology in DA, 
but was rather inconclusive and the direction of the relation between psychiatric 
symptomatology and DA remained speculative. 
In Chapter 3 we studied the intensity of psychiatric symptoms in patients with 
DA. The intensity of psychiatric symptoms was higher compared to the general 
population and close to that found in outpatient psychiatric populations. In 
addition, the intensity of psychiatric symptoms had a stronger association with 
health related wellbeing in patients with DA compared to well-known asthma 
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related parameters like age, gender, BMI, airway obstruction and exercise 
performance. 
An interesting and unexpected fi nding was the lack of difference of the intensity 
of psychiatric symptoms and perceived wellbeing between males and females 
with DA. In general, females tend to report psychiatric symptoms more often 
compared to men [8]. One would expect to fi nd a similar difference in the 
present sample especially since female patients with asthma also tend to 
report more asthma symptoms and worse health related wellbeing compared 
to male patients, despite having similar or better lung function [9]. Therefore 
in assessing and treating patients with DA, we should not only consider high 
intensity of psychiatric symptoms in females but also consider high intensity of 
psychiatric symptoms in males. 
In Chapter 4 we studied psychiatric problems at syndrome level in patients with 
DA. Over half (54,9%) of patients with DA had one or more psychiatric disorder 
and 89,3% of these disorders was previously unrecognized. More specifi cally, 
49% of all patients with DA had a major mental disorder. This prevalence was 
higher in comparison to the 31–34% reported [10, 11] in asthmatic outpatients, 
including both ‘normal’ asthmatic patients and patients with diffi cult asthma. 
The prevalence of 49% of major mental disorders was also substantially higher 
in comparison to that of the general population in the USA (26.6%) [12] and in 
The Netherlands (18%) [13]. Similarly, the prevalence of personality disorders 
in DA of 19.6% in the current study was also substantially higher compared to 
the general population in the USA (9%) [14] and in The Netherlands (13.5%) 
[15].
We may conclude from the two empirical studies that psychopathology at both 
symptom and syndrome level is highly prevalent in DA. Especially the high 
prevalence at syndrome level is important because it emphasizes the severity of 
psychopathology in DA. Psychiatric symptoms can be subclinical but psychiatric 
syndromes may infl uence everyday life and hence warrant specifi c treatment. 
Another important fi nding was that psychiatric symptoms appeared to have a 
stronger association with perceived wellbeing compared to age, gender, BMI, 
airway obstruction and exercise performance. Health related wellbeing is widely 
accepted as an important marker of progress made by a patient in rehabilitation 
[16]. Therefore diagnostics into and treatment of psychiatric symptoms and 
syndromes appeared to be important in patients with DA. 
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Besides psychiatric symptoms and syndromes, alexithymia (affective-cognitive 
emotion-regulation) is also considered a major complicating factor in DA [17]. 
Most patients diagnosed with DA seem not able to adequately perceive signals 
of forthcoming exacerbations -emotions or physical signs- and hence over- 
or underreact to these signals [18, 19]. This over- or under perception can 
be a consequence of a psychological condition named ‘alexithymia’.  As such 
the introduction of the concept of  “alexithymia” may contribute to a better 
understanding of the mechanisms resulting in DA and provide us with treatment 
opportunities for DA. Our review of the available empirical literature in Chapter 
5 showed a high prevalence of alexithymia in asthma: between 14,7% and 36%, 
which was higher compared to the general population (13%) [20]. This review 
also suggested that alexithymia is related to asthma in general and specifi cally to 
more severe asthma symptoms. There was also a relation between alexithymia 
on the one hand and worse asthma control and lower quality of life on the other 
hand.  The suggestion that alexithymia is a patient related factor in asthma, and 
may possibly be related to worse asthma [21, 22] seemed to be confi rmed by 
the review. 
Specialized pulmonary rehabilitation
As psychological factors may play a role in the etiology and maintenance of 
DA, we studied the outcome of existing well-established rehabilitation programs 
consisting of both physical and psychological elements –a multidisciplinary 
treatment. Specialized health care psychologists assessed all patients and treated 
positive cases with individualized psychological treatment, which consisted also 
of group-based psychosocial counseling sessions. Our study in Chapter 6 in DA 
patients demonstrated that such specialised pulmonary rehabilitation programs 
might contribute to improved health related wellbeing in patients with DA and 
that this improvement might persist at longitudinal follow up, i.e. 12 months 
post-rehabilitation.  Health related wellbeing improved signifi cantly along with 
signifi cant improvement of psychiatric symptoms during rehabilitation. Due to 
limitations of the design no data were available with regard to possible changes 
in exacerbation frequency.  
Based on the results of our studies in Chapter 2 and 3, wherein psychiatric 
symptoms seemed to pose as complicating factors in the treatment of DA 
[7], we hypothesized that the level of psychiatric symptoms at the start of 
the rehabilitation would negatively infl uence outcome of the rehabilitation. 
Specifi cally, we hypothesized that the improvement during rehabilitation would 
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be smaller if the level of psychiatric symptoms was higher at the start of the 
rehabilitation. In contrast to what we expected, there was no relation between 
psychiatric symptoms at baseline and the progress made on health related 
wellbeing during rehabilitation. It is most likely that since there was a signifi cant 
amount of psychological interventions in the specialist PR programme, psychiatric 
symptoms were treated well enough not to interfere with the “physical elements” 
of the PR programme, making this programme suitable for patients with DA.  
GENERAL DISCUSSION
THEORETICAL AND POSSIBLE CLINICAL IMPLICATIONS
At the start of this thesis a potential role of psychological factors in the etiology 
and maintenance of DA was only confi rmed by a small amount of papers on 
psychological subjects in DA. This thesis tried to complement existing literature on 
psychopathology in DA and to create an empirical base for existing management 
programs for DA. The main aim of this thesis was to gain a better understanding 
of DA from a psychological point of view.
Existing scarce literature confi rmed the presence of high intensity of psychiatric 
symptoms in DA (Chapter 2). Our research also confi rmed this high intensity of 
psychiatric symptoms and syndromes (Chapter 3 and 4). Besides anxiety and 
depression, other psychiatric symptoms and syndromes were also present in DA. 
It is therefore advisable to study the broad spectrum of psychiatric syndromes 
in DA. For example, specifi cally obsessive compulsive personality disorder was 
relatively frequent in DA. 
Although this thesis confi rmed the high frequency of psychiatric symptoms 
and syndromes in DA, its role in the etiology and maintenance of DA remains 
uncertain. The direction of the relation between psychiatric symptoms and 
syndromes may be bi-directional; DA may result in psychiatric symptoms 
and syndromes and in alexithymia and/or vice versa.  More research, in 
particular longitudinal research also involving other psychological factors like 
patient compliance, coping strategies, social economic status and less known 
factors like resilience and attachment styles- on psychological factors in DA 
and specifi cally path analyses are necessary to create an empirical base of 
theories on psychological factors in the etiology and maintenance of DA. For 
future research combining this psychological approach with a pathophysiological 
approach, a biopsychosocial approach, would probably give even more insight 
into the etiology and maintenance of DA. This thesis did create an empirical base 
for such a theory because we provided evidence that psychiatric symptoms and 
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syndromes are highly prevalent in DA. Future research may focus on the role and 
direction of psychological factors, best in combination with pathophysiological, 
in DA. 
The question whether treatment of DA also treats psychiatric symptoms and 
syndromes and/or vice versa is interesting for future clinical research. In general, 
psychiatric symptomatology is more prevalent in women, in DA the intensity 
was equally high in both men and women (Chapter 3). Although screening 
of psychopathology is advised at an early stage of asthma in GINA-guidelines, 
psychiatric symptoms and syndromes are still easily overlooked, even in highly 
specialized care: up to 80% of the DA patients who suffered from a psychiatric 
syndrome was undiagnosed at time of assessment. This is probably because of 
the rather dramatic somatic manifestation of the disease, a defi nition that is 
based on pharmacological treatment and a fear of stigmatizing in both the eyes 
of patient and doctor.
Psychological factors, i.e. psychiatric symptoms and syndromes and 
alexithymia, play an important role in health related wellbeing in DA. However, 
our thesis did not confi rm psychiatric symptoms being a complicating factor 
of successful specialized pulmonary treatment. Although psychiatric symptoms 
seemed to occur frequently in DA, the improvement of health related wellbeing 
during rehabilitation suggests that psychiatric symptomatology is no contra-
indication for specialized rehabilitation. Psychiatric symptoms decreased during 
rehabilitation. Future research should show if this is a result of the specifi c 
multidisciplinary treatment incorporating also psychological interventions. It is 
also still uncertain whether psychiatric symptoms are complicating factors in 
non-specialized care. This again also questions the role of psychiatric symptoms 
in DA and thus causality. It is important to specifi cally study whether the 
psychological interventions in specialized pulmonary rehabilitation prevent 
psychiatric symptoms interfering with treatment outcome or whether psychiatric 
symptoms are just a comorbid condition, which is more frequent in DA but 
does not complicate treatment. In addition, if specifi c interventions prevent 
interference, these could possibly be integrated in an earlier phase of asthma 
treatment. 
For clinical practice it is important to consider treating these comorbid 
psychiatric symptoms and syndromes after or concurrent with specialized 
pulmonary rehabilitation rather than before. Treatment of psychiatric symptoms 
and syndromes can be considered after rehabilitation because they seemed no 
contra-indication for rehabilitation. Patients do need treatment because of the 
relation with poorer health related wellbeing in DA. In addition, although there 
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was a signifi cant reduction of psychiatric symptoms during rehabilitation, it is 
unknown if these are reduced to a subclinical level. This needs to be addressed 
in future research.
Referral to easy accessible psychological care in an early stage in Primary 
Care, like the POH-GGZ – a nurse-practitioner specialized in mental health 
care - in The Netherlands does seem advisable. However, once DA has been 
diagnosed, psychiatric evaluation should certainly be included in the standard 
medical examinations of patients with DA. Referral to a specialized health care 
psychologist or psychiatrist is advised, already at an early phase in asthma-
care, in the hospital outpatient setting and not just until a patient has been 
referred to a specialized pulmonary rehabilitation center. The under-diagnosis 
and hence under-treatment of both psychiatric symptoms and syndromes and 
the possible role of alexithymia in DA should be minimized in order to reduce as 
much as possible the burden of patients with DA and their environment. 
Probably because of the dramatic manifestation of asthma symptoms in DA, it 
is diffi cult to discriminate between psychiatric and asthma symptoms, not only 
for patients but also for pulmonologists. Awareness of the possible presence 
of psychiatric symptoms and syndromes may sensitize professionals working 
with asthma patients to overcome this problem. In addition, at least in The 
Netherlands, there is still a stigma on psychiatric diseases. This may result in 
unwillingness to acknowledge and accept psychiatric symptoms [23]. 
The role of alexithymia should also be taken into account in DA, as it makes 
it more diffi cult for patients not only to differentiate between emotions and 
bodily sensations but also to communicate their physiological and psychological/
psychiatric symptoms to health care professionals. Alexithymia should therefore 
also be considered when interpreting the reporting of symptoms by patients with 
DA. Communicating their symptoms, and understanding them, is more diffi cult 
for these patients and could obscure the assessment of the clinical condition and 
hence complicate treatment.
Alexithymia appeared to be present in a substantial part of patients with DA 
and could be an explanation of the clinical observation that DA patients often 
cannot detect early warning symptoms preceding exacerbations or mistake 
asthma symptoms for emotions and over-report symptoms. As a consequence, 
at least in a number of patients, alexithymia might partially maintain the DA-
symptomatology. Awareness of the possible presence of alexithymia by health 
care professionals and patients may improve treatment (Chapter 5), by 
incorporating (existing) therapies involving treatment of alexithymia. Such a 
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therapeutic approach should differentiate between patients that over- and those 
that under-perceive signs and symptoms of asthma. A ‘new’ area of research 
exploring the role of alexithymia in the etiology and treatment outcome of DA is 
recommended. When higher levels of alexithymia are present in a DA patient, a 
multidisciplinary approach (outpatient or in a rehabilitation center) is probably 
the best setting to diagnose and treat this problem because psychological factors 
and physiological factors can be unraveled and the patient can learn how to 
differentiate between emotions and feelings versus asthma symptoms. 
Treatment of alexithymia in asthma –and especially in DA- could be an 
opportunity in the management of asthma, because it is known that alexithymia 
is important in the etiology and maintenance of other somatic chronic diseases 
[24]. Moreover, in these chronic conditions, treatment targeting at better 
perception of physical and emotional signals resulted in less symptoms [24]. 
Until now, no studies on the treatment of alexithymia in asthma have been 
reported. 
We propose a different approach towards the understanding, assessment 
and treatment of asthma/DA. Although GINA tries to bridge between psyche 
and soma, in our view, a more integrated view of asthma/DA needs to be 
developed. Such a view should increase awareness at an early stage whether 
psychiatric symptoms and syndromes and alexithymia are involved in patients 
with asthma/DA. As a consequence, this should result in a referral at an early 
stage to a physician, psychiatrist or psychologist or a combination of health 
care professionals for adequate treatment. Already in Primary Care, all asthma 
patients who do not respond adequately to the fi rst steps of the GINA guidelines 
should receive a psychological assessment by the nurse practitioner of the GP. 
If psychiatric symptoms seem to be prevalent, referral to a psychologist (within 
Primary Care) is advocated with additional focus on the possible existence 
of alexithymia. If the patient is still not responding to this (multidisciplinary) 
treatment, referral to a pulmonologist and medical psychologist of a hospital is 
advisable for further diagnostics. If psychiatric symptoms and/or alexithymia 
are predominant aspects of the asthma symptoms, referral to a pulmonary 
rehabilitation center is advisable where a more integrated treatment approach 
is readily available, as they target physical aspects, psychiatric symptoms and 
syndromes and alexithymia. 
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THEORETICAL AND PRACTICAL LIMITATIONS: 
DIFFICULT TO TREAT AND DIFFICULT TO STUDY
Complicating factors
DA, by defi nition, is an asthma subgroup, which is diffi cult to treat. An 
explanation for the diffi culty of treating DA, as shown by this thesis, is the 
possible role of psychiatric symptoms, syndromes and alexithymia. Literature 
on psychopathology in DA was scarce which made a psychological approach - 
research on psychiatric symptoms, syndromes and alexithymia - to DA appear 
to be a rather new focus. 
DA itself also appeared to be a diffi cult subgroup to study. The defi nition of 
DA is based on pharmacological treatment results instead of specifi c disease 
characteristics. DA is as a result a heterogeneous group consisting of several 
subgroups of patients with different characteristics. It is for instance questionable 
whether NFA (near fatal asthma), a subgroup of DA, is comparable to brittle 
asthma – another subgroup. One may speculate that DA is too heterogeneous. 
However, it is a group of patients that GP’s and pulmonologists see in their 
practice with a great burden for patients themselves and society. The problem 
of heterogeneity also made it diffi cult to compare the treatment outcome of the 
few studies we found on DA. 
Another complicating factor in our thesis was the rather unknown concept of 
alexithymia in both asthma and DA. Only few studies investigated the role of 
alexithymia in asthma and no specifi c studies studied alexithymia in the etiology 
of DA. In addition, no studies reported on the effect of treating alexithymia in 
asthma or DA. 
The probable presence of alexithymia in asthma also causes a specifi c problem 
of studying asthma/DA. Patients with alexithymia have diffi culty in recognizing 
both emotional and bodily sensations and putting these into words. This makes 
it diffi cult to adequately rely on self-report measures regarding feelings and 
sensations. This could in turn have infl uenced studies with self-reports on 
somatic and mental health. As a result, prevalence fi gures of psychopathology in 
asthma/DA patients assessed by self-report instruments should be interpreted 
with caution. A possible way to overcome misinterpretation of psychiatric 
symptomatology is the use of a standardized psychiatric interview. During this 
interview, the health care professional will gain more insight whether the (high 
or low) levels of symptoms is partly to be explained by alexithymia.  
Another complicating factor that needs to be mentioned and will always – by 
defi nition - infl uence research of DA, is the use of corticosteroids. Corticosteroids 
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are well known to have major psychotropic side effects, especially in chronic high 
doses, which is often the case in DA [25, 26]. Psychiatric distress is heightened 
in patients with severe prednisone dependent asthma [25] and the use of oral 
corticosteroids is related to lower quality of life [26]. A possible independent 
effect of this medication on major mental disorders should be taken into account 
[27] in future studies.
Strengths and limitations
This thesis has several strengths and limitations. A fi rst strength is that we 
studied our patient group with only limited exclusion criteria. As a consequence 
however, this resulted in a heterogeneous group in which it is questionable 
whether results can be generalized to all DA patients in all settings. In addition, 
patients with severe psychopathology that could interfere with treatment 
were excluded in the three empirical studies in this thesis. This also limits 
generalizability. 
Another strength is that we used well-validated instruments, including interviews 
for diagnosing psychiatric syndromes for both major mental disorders and 
personality disorders.  
This thesis studied both the intensity of psychiatric symptoms and the presence 
of psychiatric syndromes. A limitation is that the use of self-reports could have 
resulted in a bias because of probable high intensity of alexithymia in DA. 
However, the interviews also showed high frequency of psychiatric syndromes, 
suggesting that indeed DA patients suffer from high intensity of psychiatric 
symptoms, a fi nding also found in other studies. In addition, as mentioned above, 
patients with severe psychopathology which could interfere with treatment 
were excluded, which could also diminish the frequency of psychopathology in 
our samples. This therefore emphasizes that patients with DA suffer from high 
intensity of psychiatric symptoms. 
We studied the relation between the intensity of psychiatric symptoms and 
specialized treatment. In this naturalistic study, however, psychological 
interventions were individualized resulting in (a) not knowing if and which 
interventions resulted in the best outcome, and (b) not knowing if these 
interventions prevented psychiatric symptoms from interfering with treatment 
outcome. In addition, we combined psychological measures with physiological 
measures in a limited way. In future research it is important to broadly measure 
on both dimensions. Since RCT’s are less desirable in the research of these 
patients, single case designs could provide further insight in the differing types 
of DA patients. 
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There is a proportion of patients with DA who do not report psychiatric 
symptoms and/or alexithymia. This thesis did not clarify which factors in these 
patients without high intensity of psychiatric symptoms and alexithymia are 
complicating DA. Therefore more research on DA is necessary discriminating 
between different types of DA patients in order to fi nd out which interventions 
are preferentially applicable for which patients. As a result, a more differentiated 
treatment approach could become more effective. 
CONCLUSIONS 
This thesis provides empirical evidence that psychiatric symptoms and 
syndromes are highly prevalent and often unrecognized in DA, irrespective of 
gender. Specialized pulmonary rehabilitation may be benefi cial for patients with 
DA with long lasting effect on health related wellbeing. Psychiatric symptoms 
are no contra-indication for treatment and improve also during rehabilitation. 
Early referral for psychological assessment and treatment is recommended for 
patients with DA. Alexithymia is probably also highly prevalent in asthma and 
DA and needs further research. Future research should use a more integrated 
approach including both psychological and pathophysiological aspects. 
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SAMENVATTING VAN DE VOORNAAMSTE BEVINDINGEN
Normaliter is astma een goed behandelbare chronische ziekte waarbij desondanks 
5% van de patiënten niet goed reageert op reguliere (farmacologische) 
behandeling en lijdt aan moeilijk behandelbaar astma (Diffi cult Asthma: DA) [1]. 
Deze patiënten hebben zeer ernstige beperkingen in hun dagelijkse bezigheden, 
ze consumeren een signifi cant gedeelte van de door astma patiënten gebruikte 
medische hulp, lijden aan frequente exacerbaties, zijn vatbaar voor medische 
complicaties [2-4] en ze hebben een lage kwaliteit van leven [5]. DA vormt 
een relatief zware last voor de maatschappij [6]. Factoren die DA veroorzaken 
zijn tot nog toe onduidelijk. Er zijn indicaties dat –buiten somatische factoren- 
psychologische factoren mogelijk een rol spelen in de ontwikkeling en het in 
stand houden van DA. Hoewel de wereldwijd geaccepteerde aanbevelingen 
volgens GINA criteria voor het behandelen van astma in het algemeen ook 
een psychologische attitude bevatten, is empirische onderbouwing van deze 
redenering beperkt. 
Het hoofddoel van deze thesis is het beter begrijpen van DA vanuit een 
psychologisch oogpunt. Specifi ek worden twee concepten bestudeerd in relatie 
tot DA, te weten psychiatrische symptomatologie/syndromen en alexithymie. 
Deze twee concepten worden beschouwd als complicerende factoren in DA in 
zowel wereldwijde management richtlijnen en in de klinische praktijk. 
EEN PSYCHOLOGISCHE BENADERING IN HET BEGRIJPEN 
VAN MOEILIJK BEHANDELBAAR ASTMA (DA)
Psychopathologie
Verschillende beschikbare empirische studies bevestigden een hogere 
prevalentie van psychiatrische symptomen en syndromen in DA in vergelijking 
met de algemene populatie, zoals beschreven is in Hoofdstuk 2. Patiënten met 
DA en comorbide psychiatrische symptomen ervoeren bovendien meer astma 
hospitalisaties en exacerbaties in vergelijking met patiënten met DA met minder 
psychiatrische symptomen [7]. De literatuur suggereerde daarnaast dat er een 
mogelijk rol was voor psychiatrische symptomatologie in DA, maar dit bleef nogal 
onduidelijk en de richting van de relatie tussen psychiatrische symptomatologie 
en DA bleef speculatief. 
In Hoofdstuk 3 bestudeerden we de intensiteit van psychiatrische symptomen 
in patiënten met DA. De intensiteit van psychiatrische symptomen was hoger 
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in vergelijking met de algemene bevolking en kwam dichtbij de intensiteit die 
gevonden wordt in ambulante psychiatrische populaties. De intensiteit van de 
psychiatrische symptomen had bovendien een sterkere associatie met welzijn 
gerelateerd aan de medische conditie in patiënten met DA vergeleken met bekende 
parameters als leeftijd, sekse, BMI (Body Mass Index), luchtwegobstructie en 
bewegingsprestaties. Een interessante en niet verwachte bevinding was het 
gebrek aan verschil in de intensiteit van psychiatrische symptomen en welzijn 
gerelateerd aan de medische conditie tussen mannen en vrouwen in DA. In 
het algemeen hebben vrouwen een grotere neiging tot het rapporteren van 
psychiatrische symptomen in vergelijking tot mannen [8]. Verwacht werd een 
gelijk verschil te vinden in de huidige populatie, zeker aangezien vrouwen 
met astma ook meer astma symptomen en slechter welzijn gerelateerd aan 
de medische conditie neigen te rapporteren in vergelijking met mannelijke 
patiënten, ongeacht vergelijkbare of betere longfunctie [9]. Derhalve zouden 
we in het onderzoeken en behandelen van patiënten met DA, niet alleen bij 
vrouwen maar ook bij mannen hoge intensiteit van psychiatrische symptomen 
moeten overwegen. 
In Hoofdstuk 4 bestudeerden we psychiatrische problemen op syndroom 
niveau in patiënten met DA. Meer dan de helft (54,9%) van de patiënten met 
DA had een of meer psychiatrische stoornissen en 89,3% van deze stoornissen 
was eerder niet onderkend. Specifi ek had 49% een psychiatrische stoornis. 
De prevalentie was hoger dan de 31-34% die gevonden wordt in astmatische 
ambulante patiënten [10,11], waarbij zowel ‘gewone’ astmatische patiënten in 
de populatie zitten als patiënten met DA. De prevalentie van 49% psychiatrische 
stoornissen was ook substantieel hoger in vergelijking met die van de algemene 
populatie in de USA (26,6%) [12] en in Nederland (18%) [13]. Evenzo was de 
prevalentie van persoonlijkheidsstoornissen van 19,6% in de huidige studie ook 
substantieel hoger dan die van de algemene populatie in de USA (9%) [14] en 
in Nederland (13,5%) [15]. 
Uit de twee empirische studies mogen we concluderen dat de prevalentie van 
psychopathologie zowel op symptoom als syndroomniveau hoog is in DA. Vooral 
de hoge prevalentie op syndroomniveau is belangrijk omdat dit de ernst van 
de psychopathologie in DA benadrukt. Psychiatrische symptomen kunnen 
subklinisch zijn maar psychiatrische syndromen beïnvloeden het alledaagse leven 
en behoeven derhalve specifi eke behandeling hiervoor. Een andere belangrijke 
bevinding was dat psychiatrische symptomen een sterkere relatie met welzijn 




gerelateerd aan de medische conditie hadden vergeleken met leeftijd, sekse, 
BMI, luchtwegobstructie en bewegingsprestaties. Welzijn gerelateerd aan de 
medische conditie wordt breed geaccepteerd als een belangrijke marker van 
vooruitgang voor een patiënt binnen de longrevalidatie [16]. Diagnostiek en 
behandeling van psychiatrische symptomen en syndromen bleek derhalve 
belangrijk in patiënten met DA. 
Alexithymie
Naast psychiatrische symptomen en syndromen wordt alexithymie (affectieve-
cognitieve emotieregulatie) ook beschouwd als een belangrijke complicerende 
factor in DA [17]. De meeste patiënten die gediagnosticeerd zijn met DA lijken 
niet in staat om adequaat signalen waar te nemen van aankomende exacerbaties 
en dus teveel of te weinig reageren op deze signalen [18,19]. Dit teveel of 
te weinig waarnemen is een onderdeel van een psychologische conditie die 
‘alexithymie’ wordt genoemd. Als zodanig kan de introductie van het concept 
‘alexithymie’ bijdragen aan een beter begrip van de mechanismen die resulteren 
in DA en ons behandelmogelijkheden voor DA geven. In Hoofdstuk 5 toonde 
de beschikbare empirische literatuur een hoge prevalentie van alexithymie aan 
in astma: tussen de 14,7% en de 36%, wat hoger is in vergelijking met de 
algemene populatie (13%) [20]. De uitkomsten van de review suggereerden 
dat alexithymie gerelateerd is aan astma in het algemeen en specifi ek aan 
meer ernstige astma symptomen. Er was ook een relatie tussen alexithymie en 
slechtere astma controle en een lagere kwaliteit van leven. De suggestie dat 
alexithymie een patiënt gerelateerde factor is en mogelijk gerelateerd is aan 
ernstiger astma lijkt bevestigd te worden door de uitkomsten van de review. 
Gespecialiseerde longrevalidatie
Aangezien psychologische factoren een rol kunnen spelen in de etiologie en het 
voortbestaan van DA, bestudeerde we de uitkomst van bestaande revalidatie 
behandelprogramma’s die bestaan uit zowel fysieke als psychologische elementen. 
Gespecialiseerde gezondheidszorgpsychologen onderzochten alle patiënten en 
behandelden patiënten met geïndividualiseerde psychologische behandeling 
welke ook in een groep konden plaatsvinden. Onze studie in Hoofdstuk 6 liet 
zien dat zo’n gespecialiseerd longrevalidatie programma kan bijdragen aan 
verbeterd welzijn gerelateerd aan de medische conditie in patiënten met DA en 
dat deze verbetering bleef op de lange termijn, dat wil zeggen 12 maanden na de 
revalidatie. Welzijn gerelateerd aan de medische conditie verbeterde signifi cant 
samen met de signifi cante verbetering van psychiatrische symptomen tijdens de 
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revalidatie. Helaas was er geen data beschikbaar met betrekking tot mogelijke 
veranderingen in de frequentie van exacerbaties. 
Gebaseerd op de resultaten in de Hoofdstukken 2 en 3, waarin psychiatrische 
symptomen complicerende factoren leken in de behandeling van DA [7], 
hypothetiseerden we dat de intensiteit van de psychiatrische symptomen 
aan het begin van de revalidatie de uitkomst van de revalidatie negatief zou 
beïnvloeden. Specifi ek hypothetiseerden we dat de verbetering tijdens de 
revalidatie kleiner zou zijn als de intensiteit van de psychiatrische symptomen 
hoger zou zijn aan het begin van de revalidatie. In contrast tot wat we verwachten 
was er geen verband tussen de intensiteit van de psychiatrische symptomen aan 
het begin en de vooruitgang die gemaakt werd op welzijn gerelateerd aan de 
medische conditie tijdens de revalidatie. Het is waarschijnlijk dat vanwege een 
behoorlijke hoeveelheid psychologische interventies tijdens de gespecialiseerde 
revalidatieprogramma’s, psychiatrische symptomen goed genoeg behandeld 
werden om in te grijpen op de ‘fysieke elementen’ van het PR programma, wat 
het programma geschikt maakt voor patiënten met DA. 
ALGEMENE DISCUSSIE
THEORETISCHE EN MOGELIJKE KLINISCHE IMPLICATIES
Aan het begin van deze thesis leek een mogelijke rol voor psychologische 
factoren voor de etiologie en het voortduren van DA enkel bevestigd in een 
kleine hoeveelheid literatuur over psychologische onderwerpen in DA. Deze 
thesis probeerde de bestaande literatuur over psychopathologie in DA aan te 
vullen en om een empirische basis te creëren voor bestaande management 
programma’s gericht op het behandelen van DA. Het hoofddoel van deze thesis 
was DA beter te begrijpen vanuit een psychologisch oogpunt. 
De beperkte bestaande literatuur bevestigde de aanwezigheid van een hoge 
intensiteit van psychiatrische symptomen in DA (Hoofdstuk 2). Ons empirisch 
onderzoek bevestigde tevens deze hoge intensiteit van psychiatrische symptomen 
en syndromen (Hoofdstuk 3 en 4). Naast angst en depressie waren er ook 
andere psychiatrische symptomen aanwezig in DA. Het is daarom raadzaam 
om het brede spectrum aan psychiatrische syndromen in DA te bestuderen. 
Specifi ek was bijvoorbeeld de obsessief compulsieve persoonlijkheidsstoornis 
relatief vaak aanwezig. 
Hoewel deze thesis de hoge frequentie en intensiteit van psychiatrische 
symptomen en syndromen in DA bevestigde, blijft de rol in de etiologie en 




voortbestaan van DA onduidelijk. De relatie tussen DA en psychiatrische 
symptomen en syndromen is waarschijnlijk tweezijdig; DA kan resulteren in 
psychiatrische symptomen en syndromen en in alexithymia of vice versa. Meer 
onderzoek naar psychologische factoren in DA, in het bijzonder longitudinaal 
onderzoek waarbij ook andere psychologische factoren meegenomen worden 
als de volgzaamheid van patiënten, coping strategieën, sociaal economische 
status en minder bekende factoren als veerkracht, hechtingsstijlen- en specifi ek 
‘path analyses’ zijn nodig om een empirische basis te creëren van een theorie 
over psychologische factoren in de etiologie en het voortbestaan van DA. Voor 
toekomstig onderzoek zal het combineren van deze psychologische benadering 
met een somatische benadering waarschijnlijk nog meer inzicht geven in 
de etiologie en voortbestaan van DA. Deze thesis heeft bijgedragen aan het 
creëren voor zo’n empirische basis omdat we bewijs gaven dat psychiatrische 
symptomen en syndromen in hoge mate aanwezig zijn in DA. 
De vraag of behandeling van DA ook de psychiatrische symptomen en syndromen 
behandelt en/of vice versa is interessant voor toekomstig klinisch onderzoek. In 
het algemeen is psychiatrische symptomatologie meer prevalent in vrouwen, 
in DA was de intensiteit even hoog in mannen als in vrouwen (Hoofdstuk 3). 
Hoewel in GINA richtlijnen het screenen van psychopathologie geadviseerd 
wordt in een vroeg stadium van astma, worden psychiatrische symptomen en 
syndromen gemakkelijk over het hoofd gezien, zelfs in zeer gespecialiseerde 
zorg: tot wel 80% van DA patiënten die lijdt aan een psychiatrisch syndroom 
was niet gediagnosticeerd tijdens de meting. Dit is waarschijnlijk vanwege de 
nogal dramatische somatische manifestatie van de ziekte, een defi nitie die 
gebaseerd is op farmacologische behandeling en een angst voor stigmatisering 
in zowel de ogen van arts als patiënt. 
Psychologische factoren, dat wil zeggen psychiatrische symptomen en 
syndromen en alexithymie, spelen een belangrijke rol in welzijn gerelateerd 
aan de medische conditie in DA. Echter, onze thesis bevestigde psychiatrische 
symptomen niet als een complicerende factor in de succesvolle gespecialiseerde 
longbehandeling. Hoewel psychiatrische symptomen frequent bleken voor te 
komen in DA, suggereert de verbetering in welzijn gerelateerd aan de medische 
conditie tijdens de revalidatie dat psychiatrische symptomatologie geen contra-
indicatie is voor gespecialiseerde revalidatie. Psychiatrische symptomen namen 
af tijdens de revalidatie. Toekomstig onderzoek zou moeten uitwijzen of dit een 
gevolg is van de specifi eke multidisciplinaire behandeling die tevens bestond 
uit psychologische interventies. Het is daarnaast nog altijd onduidelijk of 
psychiatrische symptomen complicerende factoren zijn in niet gespecialiseerde 
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zorg. Dit maakt ook de rol van psychiatrische symptomen in DA twijfelachtig en 
dus ook de vraag naar causaliteit. Het is belangrijk om specifi ek te bestuderen 
of psychologische interventies in gespecialiseerde longrevalidatie voorkomen 
dat psychiatrische symptomen interfereren met de behandeluitkomst of dat 
psychiatrische symptomen slechts een comorbide conditie zijn die weliswaar 
meer en ernstiger aanwezig zijn in DA maar de behandeling niet compliceert. 
Bovendien is het zo dat wanneer specifi eke interventies interferentie tijdens de 
behandeling voorkomt, deze interventies mogelijk geïntegreerd kunnen worden 
in een eerdere fase van astma behandeling. 
Voor de klinische praktijk is het belangrijk om te overwegen deze comorbide 
psychiatrische symptomen en syndromen te behandelen na of tijdens de 
gespecialiseerde longrevalidatie in plaats van voor de revalidatie. Behandeling 
van psychiatrische symptomen en syndromen kan overwogen worden na de 
revalidatie omdat ze geen contra-indicatie bleken te zijn. Patienten hebben wel 
behandeling nodig vanwege de relatie met slechter welzijn gerelateerd aan de 
medische conditie in DA. Hoewel er een duidelijke signifi cante vermindering 
van psychiatrische symptomen was tijdens de behandeling is het bovendien 
onduidelijk of deze symptomen verminderd zijn tot een subklinisch niveau. Dit 
moet in de toekomst onderzocht worden.  
Verwijzing naar makkelijk toegankelijke psychologische zorg in een vroeg stadium 
in de eerste lijn, zoals de POH-GGZ in Nederland, een praktijkondersteuner 
gespecialiseerd in geestelijke gezondheidszorg wordt alsnog geadviseerd. Echter, 
zodra DA is gediagnosticeerd, zou psychiatrische evaluatie zeker geïncludeerd 
moeten worden in de standaard medische onderzoeken van patiënten met DA. 
Verwijzing naar gespecialiseerde gezondheidszorgpsycholoog of psychiater 
wordt reeds in een vroeg stadium in de astma zorg geadviseerd, in de ziekenhuis 
ambulante setting en niet alleen zodra of nadat een patiënt verwezen wordt 
naar een gespecialiseerd longrevalidatie centrum. De onder diagnostisering en 
daarom onderbehandeling van zowel psychiatrische symptomen en syndromen 
en de mogelijke rol van alexithymie in DA zou geminimaliseerd moeten 
worden om zoveel mogelijk de last van patiënten met DA en hun omgeving te 
verminderen. 
Het is waarschijnlijk vanwege de dramatische manifestatie van de astma 
symptomen in DA moeilijk om het verschil te zien tussen psychiatrische en 
astma symptomen, niet alleen voor patiënten zelf maar ook voor longartsen. Het 
bewust zijn van de mogelijke aanwezigheid van psychiatrische symptomen en 
syndromen kan professionals die met astma patiënten werken gevoelig maken 
om dit probleem te verhelpen. Bovendien, in ieder geval in Nederland, is er nog 




steeds stigma over psychiatrische ziektes. Dit kan resulteren in de onbereidheid 
om psychiatrische symptomen te erkennen en te accepteren [23]. 
Alexithymie zou ook overwogen moeten worden in DA, aangezien dit het voor 
patiënten niet alleen moeilijker maakt om te differentiëren tussen emoties 
en lichamelijke sensaties maar ook om hun somatische en psychologische/
psychiatrische symptomen te communiceren met gezondheidszorg 
professionals. Alexithymie zou daarom in overweging genomen worden wanneer 
de gerapporteerde symptomen door DA patiënten geïnterpreteerd worden. 
Het communiceren van hun symptomen en het begrijpen, is moeilijker voor 
deze patiënten en kan het onderzoek van de klinische conditie bemoeilijken en 
daardoor de behandeling compliceren. 
Alexithymie bleek aanwezig te zijn in een substantieel deel van patiënten met 
DA en kan daardoor een verklaring zijn van de klinische observatie dat DA 
patiënten vaak vroege waarschuwingssignalen voorafgaand aan exacerbaties 
niet kunnen detecteren of zich vergissen in astma symptomen en emoties en 
teveel symptomen rapporteren. 
Als een consequentie, in ieder geval in een aantal patiënten, kan alexithymie 
mogelijk deels het voortbestaan van DA symptomen verklaren. Het bewustzijn van 
de mogelijke aanwezigheid van alexithymie door gezondheidszorgprofessionals en 
patiënten kan behandeling verbeteren (Hoofdstuk 5) door het incorporeren van 
(bestaande) therapieën die alexithymie behandelen. Zo’n therapeutische aanpak 
zou onderscheid moeten maken tussen patiënten die tekenen en symptomen 
van astma teveel of te weinig waarnemen. Een ‘nieuw’ gebied van onderzoek 
die de rol van alexithymie kan onderzoeken in de etiologie en behandeluitkomst 
van DA wordt derhalve aanbevolen. Wanneer hogere intensiteit van alexithymie 
aanwezig is in een patiënt met DA, is een multidisciplinaire aanpak (ambulant 
of in een revalidatiecentrum) mogelijk de beste setting om dit probleem te 
diagnosticeren en behandelen zodat psychologische en somatische factoren 
uit elkaar gehaald kunnen worden en de patiënt kan leren om onderscheid te 
maken tussen emoties en gevoelens versus astma symptomen. 
Behandeling van alexithymie in astma –en specifi ek in DA- kan een kans zijn 
in de behandeling van astma, omdat het bekend is dat alexithymie belangrijk 
is in de ontwikkeling en het voortbestaan van andere somatische chronische 
ziektes [24]. Bovendien resulteerde behandeling gericht op betere waarneming 
van somatische en emotionele signalen in minder symptomen [24]. Tot nog toe 
zijn er geen studies over de behandeling van alexithymie in astma bekend. 
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Wij stellen een andere benadering voor ten aanzien van het begrijpen, 
onderzoeken en de behandeling van astma/DA. Hoewel GINA probeert een brug 
te slaan tussen psyche en soma, moet er ons inziens, een meer geïntegreerde 
kijk op astma/DA ontwikkeld worden. Zo’n kijk zou het bewustzijn in een vroeg 
stadium moeten bevorderen of psychiatrische symptomen en syndromen en 
alexithymie aanwezig zijn in patiënten met astma/DA. Als een consequentie, 
zou dit moeten resulteren in verwijzing in een vroeg stadium naar een arts, 
psychiater of psycholoog of een combinatie van gezondheidzorgprofessionals 
voor adequate behandeling. Reeds in de eerste lijn, zouden alle patiënten die 
niet adequaat reageren op de eerste stappen in de GINA richtlijnen psychologisch 
onderzoek moeten krijgen door een praktijkondersteuner GGZ van de huisarts. 
Wanneer psychiatrische symptomen aanwezig blijken te zijn, wordt verwijzing 
naar een psycholoog in de eerste lijn geadviseerd met daarnaast een focus op 
de mogelijke aanwezigheid van alexithymie. Wanneer de patiënt niet reageert 
op deze (multidisciplinaire) behandeling, wordt verwijzing naar een longarts en 
medische psycholoog van een ziekenhuis geadviseerd voor verdere diagnostiek. 
Wanneer psychiatrische symptomen en alexithymie een belangrijk aspect zijn 
astma wordt verwijzing naar een longrevalidatiecentrum geadviseerd waar een 
meer geïntegreerde  somatische/psychologische behandeling beschikt baar is, 
aangezien daar zowel de somatische aspecten als psychiatrische symptomen en 
syndromen en alexithymie benaderd worden. 
THEORETISCHE EN PRAKTISCHE LIMITATIES
MOEILIJK TE BEHANDELEN EN MOEILIJK TE BESTUDEREN
Complicerende factoren
DA is, bij defi nitie, een astma subgroep die moeilijk te behandelen is. Een 
verklaring voor de moeilijkheid in de behandeling van DA, zoals aangetoond 
in deze thesis, is de mogelijke rol van psychiatrische symptomen, syndromen 
en alexithymie. Literatuur over psychopathologie in DA was beperkt waardoor 
een psychologische benadering -onderzoek naar psychiatrische symptomen, 
syndromen en alexithymie- ten aanzien van DA een nieuwe focus leek. 
DA zelf bleek tevens een moeilijke subgroep om te bestuderen. De defi nitie van 
DA is gebaseerd op farmacologische behandeling in plaats van specifi eke ziekte 
karakteristieken. DA is daardoor een heterogene groep die bestaat uit diverse 
subgroepen van patiënten met verschillende karakteristieken. Het is bijvoorbeeld 
twijfelachtig of NFA (near fatal asthma), een subgroep van DA, vergelijkbaar is 
met ‘brittle asthma’- een andere subgroep. Mogelijk is DA te heterogeen. Het is 




echter een groep van patiënten die huisartsen en longartsen zien in hun praktijk 
die een grote last vormen voor zowel hen zelf als de maatschappij. Het probleem 
van de heterogeniteit maakte het tevens moeilijk om behandeluitkomsten te 
vergelijken van de paar studies die we gevonden hebben. 
Een andere complicerende factor was een nogal onbekend concept van 
alexithymie in zowel astma als DA. Slechts een paar studies onderzochten 
de rol van alexithymie in astma en geen enkele specifi eke studie onderzocht 
alexithymie in de etiologie van DA. Bovendien rapporteerde geen enkele 
studie over het effect van het behandelen van alexithymie in astma of DA. 
De mogelijke aanwezigheid van alexithymie in astma veroorzaakte ook een 
specifi ek probleem in het bestuderen van astma/DA. Patiënten met alexithymie 
hebben moeite om zowel emotionele als somatische sensaties te herkennen 
en deze onder woorden te brengen. Dit maakt het moeilijk om adequaat te 
vertrouwen op zelfrapportage meetinstrumenten ten aanzien van gevoelens en 
sensaties welke ook verwerkt zijn in de review studies en sommige van onze 
eigen studies. Daarom is het belangrijk de prevalentie van psychopathologie 
in astma/DA patiënten die onderzocht is met zelfrapportage instrumenten met 
voorzichtigheid te interpreteren. Een mogelijke manier om de misinterpretatie 
van psychiatrische symptomatologie te overwinnen is het gebruik van een 
gestandaardiseerd psychiatrisch interview. Tijdens dit interview krijgt een 
gezondheidszorgprofessional meer inzicht in de (hoge of lage) intensiteit van 
symptomen welke verklaard kunnen worden door alexithymie. 
Een andere complicerende factor die genoemd moet worden en altijd –bij 
defi nitie-het onderzoek naar DA beïnvloedt, is het gebruik van corticosteroïden. 
Corticosteroïden zijn bekend om hun behoorlijke psychotropische bijwerkingen 
te hebben, zeker in chronische hoge doseringen, zoals het geval is in DA [25, 
26]. De psychiatrische last is verhoogt in patiënten met ernstig prednison 
afhankelijk astma [25] en het gebruik van orale corticosteroïden is gerelateerd 
aan lager kwaliteit van leven [26]. Een mogelijk onafhankelijk effect van deze 
medicatie op psychiatrische stoornissen zou in overweging genomen moeten 
worden in toekomstige studies [27].
Sterke punten en limitaties
Deze thesis heeft verschillende sterke punten en limitaties. Een eerste sterk 
punt is dat we onze patiëntengroep bestudeerden met slechts beperkte exclusie 
criteria. Dit resulteerde echter in een heterogene groep waarbij het twijfelachtig 
is of de resultaten gegeneraliseerd kunnen worden naar alle DA patiënten in 
alle settingen. Bovendien werden patiënten met ernstige psychopathologie die 
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konden interfereren met de behandeling ge-excludeerd in de drie empirische 
studies in deze thesis. Dit beperkt tevens de generaliseerbaarheid. 
Een ander sterk punt is het gebruik van goed gevalideerde instrumenten, 
waaronder interviews in het diagnosticeren van psychiatrische stoornissen 
waaronder persoonlijkheidsstoornissen. 
Deze thesis bestudeerde zowel de intensiteit van de psychiatrische symptomen als 
de aanwezigheid van psychiatrische syndromen. Een limitatie is dat het gebruik 
van zelfrapportage instrumenten geresulteerd kan hebben in een bias (fout) 
vanwege mogelijk hoge niveaus van alexithymie in DA. De interviews toonden 
echter ook hoge niveaus van psychiatrische syndromen aan, suggereerden dat DA 
patiënten lijden aan hoge niveaus van psychiatrische symptomen wat ook gezien 
wordt in andere studies. Bovendien, zoals boven opgemerkt, werden patiënten 
met ernstige psychopathologie bij wie de psychiatrische symptomen/syndromen 
behandeling konden interfereren ge-excludeerd, wat ook de frequentie van 
psychopathologie in onze samples kon verminderen. Dit benadrukt daarom dat 
veel patiënten met DA lijden aan hoge niveaus van psychiatrische symptomen. 
We bestudeerden de relatie tussen de intensiteit van de psychiatrische symptomen 
en gespecialiseerde behandeling. Helaas werden psychologische interventies 
geïndividualiseerd wat resulteerde in (a) niet weten of en welke interventies 
resulteerden in de beste uitkomsten, (b) niet weten of deze interventies ervoor 
zorgden dat psychiatrische symptomen daardoor niet interfereerden met de 
behandeluitkomst. Daarnaast combineerden we nauwelijks psychologische 
meetinstrumenten met somatische. In toekomstig onderzoek is het belangrijk 
om op beide dimensies te meten. Aangezien RCT’s niet wenselijk zijn in het 
onderzoek van deze patiënten, kunnen single case designs meer inzicht geven 
in de verschillende typen DA patiënten. 
Er zijn ook patiënten met DA die geen psychiatrische symptomen rapporteren 
of alexithymie. Het is niet duidelijk welke factoren in deze patiënten de 
astma compliceren. Het is daarom nodig om meer onderzoek te doen in DA 
naar verschillende typen DA patiënten om te onderzoeken welke interventies 
de voorkeur hebben bij welke patiënten. Dit kan resulteren in een meer 
gedifferentieerd behandelaanbod die effectiever is. 
CONCLUSIES
Deze thesis voorziet in empirisch bewijs dat psychiatrische symptomen en 
syndromen hoog prevalent zijn en vaak niet herkend worden in DA, ongeacht 
sekse. Gespecialiseerde longrevalidatie is mogelijk gunstig voor patiënten met 




DA met langdurende effecten op welzijn gerelateerd aan de medische conditie. 
Psychiatrische symptomen zijn geen contra-indicatie voor de behandeling en 
verbeteren tevens tijdens de revalidatie. Vroege verwijzing voor psychologisch 
onderzoek en behandeling wordt aanbevolen voor patiënten met DA. Alexithymie 
is mogelijk tevens in hoge mate aanwezig in astma en DA en behoeft meer 
onderzoek. Toekomstig onderzoek zou een meer geïntegreerde aanpak kunnen 
gebruiken waarbij zowel psychologische als somatische aspecten geïntegreerd 
worden. 
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Het was een lange weg die nu uiteindelijk in 2016 resulteert in een promotie. 
Met name de weg ernaartoe was lang, al heb ik de laatste loodjes als het zwaarst 
ervaren. 
Ergens in 2005/2006 begon deze weg bij Eikenboom. Ik mocht het onderzoek 
van Lucie Veselka ondersteunen naast klinisch werk, wat ik beiden erg leuk 
vond. Het ondersteunen nam steeds grotere vormen aan waarbij ik gaandeweg 
ook stagiaires mocht gaan begeleiden en zelfs mocht gaan nadenken over zelf 
een promotie-onderzoek opstarten. Dat bleek nog wel ingewikkeld te zijn. Want 
wat wil je dan onderzoeken? 
In het begin hebben Maarten van Son en Onno van der Hart en later Patrick 
Luyten mij hierin ondersteund en begeleid, maar dit bleek alsnog ingewikkeld 
voor mij. Ik kwam in het kader van Lucie’s onderzoek bij Heideheuvel terecht 
waar ik een voor mij interessante populatie tegen kwam en soma en psyche 
een zeer ingewikkelde combinatie bleek. Ook de combinatie met klinische 
werkzaamheden en later mijn ziek zijn, vlotte niet in het daadwerkelijk tot een 
project komen. 
Eenmaal op Heideheuvel jaren later toen ik besloten had een promotieonderzoek 
door te zetten, bracht Maarten mij in contact met Victor Pop en Antoinette 
Pommer. Toen begon het project meer vorm aan te nemen. 
Allereerst wil ik daarom mijn promotoren bedanken voor hun vertrouwen in mij 
om deze weg met mij te bewandelen. 
Beste Maarten, je was als een rots in de branding die er vanaf het begin af aan 
bij is geweest. Ik heb me altijd erg gesteund gevoeld en me wel eens afgevraagd 
wanneer je klaar was met deze eindeloze begeleiding en ondersteuning wat 
uiteindelijk zou moeten leiden tot een promotie. In je verschillende rollen ‘als 
advocaat van de duivel’ of als ‘beste stuurman aan wal’ bleef je immer zeer 
prettig in je feedback. 
Beste Victor, ook jij bleek een rots te zijn naast Maarten die me wist te prikkelen 
wanneer nodig en zeer duidelijk kon zijn wat ik erg heb kunnen waarderen. 
Vooral van jullie samen heb ik buiten de vruchtvolle ontmoetingen met 
betrekking tot mijn promotie, erg genoten van jullie vriendschap en wil jullie dan 
ook bedanken dat ik daar een stukje van heb mogen meegenieten. Toch is dat 
afwassen wat jullie doen, soms wat teveel van het goede waarbij kritische noten 
naar voren kwamen waar ik vervolgens weer wat moois van mocht maken. Wat 
tegelijkertijd altijd vruchtbaar en terecht bleek te zijn. 
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Naast mijn promotoren, ben ik jou Jan-Willem, co-promotor, ook erg dankbaar. 
Mede door de mogelijkheden die je mij gaf, was het mogelijk om te promoveren 
naast alle andere zaken waar ik mee bezig was. Je was daarnaast erg betrokken 
en reageerde altijd snel en vanuit oorden waar ik het niet altijd vandaan 
verwachtte. 
De collegae die mij geholpen hebben met de aanloop tot mijn promotie wil ik 
ook hartelijk bedanken voor hun bijdrage. Onno van der Hart, dank voor het 
meedenken en überhaupt vragen of ik een promotie wat zou vinden. Zonder 
deze vraag was ik waarschijnlijk nooit begonnen. En dank je Lucie Veselka, voor 
je enthousiasme en het meenemen in jouw proces. Samen hebben we heel wat 
mogen meemaken en heb ik veel van je mogen leren. Inmiddels ben je meer 
dan een collega geworden. Patrick Luyten, ook jou wil ik bedanken voor de meer 
psychodynamische invalshoek, al heb ik uiteindelijk nooit de ruimte gevonden 
om daar meer onderzoek naar te doen. Ik vraag me nog altijd af wanneer de 
wereld daar klaar voor is. Dank in ieder geval voor je vertrouwen en begeleiding. 
De verschillende co-auteurs met wie ik heb mogen samenwerken wil ik 
tevens bedanken voor hun bijdrages en wat ik van hen heb mogen leren. 
Natuurlijk Martina Buhring, Dirk van Ranst en specifi ek Ton van Keimpema, een 
inspiratiebron en kennisbron op het gebied van longziektes. 
Alle collegae van zowel Eikenboom als Heideheuvel die op de achtergrond 
inspiratie hebben gegeven voor mijn onderzoek wil ik bedanken. Ook de 
interesse vanuit psychologen praktijk Bos en Lommer, in het bijzonder Casper 
Koene, Walter Brania en Robert Suyl, hebben ook geholpen in het doorzetten 
van het promotie-onderzoek.  
Mijn paranimfen Lucie en Antoinette wil ik bedanken omdat ze een belangrijke 
rol in mijn onderzoek hebben gehad. Zonder Lucie zou ik dit avontuur nooit 
begonnen zijn en zonder Antoinette had ik het nooit afgemaakt. 
Omdat de promotie altijd op de achtergrond speelde en eigenlijk nooit op de 
voorgrond, was het ook een wat eenzaam project waar ik veel tijd en energie 
in heb gestoken. Mijn familie en vrienden wil ik daarom vooral bedanken in het 
bieden van de nodige afwisseling en ontspanning. 




Lieve Micha, mijn ridder op het witte paard J, mijn redder in nood, dank dat 
je er al die jaren voor me geweest bent. Op de momenten dat ik het niet meer 
zag zitten en ermee wilde stoppen, wist jij me te overtuigen om het toch af te 
maken. Je zorgde er ook voor dat ik de ruimte had om te doen wat nodig was. 
Het laatste half jaar was het meest pittig. Met Sterre erbij, al kruipend en wel, 
was het helemaal pittig. Ik wilde mijn tijd niet meer aan andere zaken dan 
Sterre spenderen. Dan nog promoveren, de laatste loodjes afmaken, naast de 
andere dingen die moeten, werd heel ingewikkeld en moeizaam. 
Lieve Sterre, dank je dat je me iedere dag laat zien wat belangrijk is in dit leven!
En nu, nu is het klaar!
Lonneke 
Augustus 2016
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A
Lonneke Kanters-Prins was born on 2 maart 1981 in Zeist. In 2000 she 
graduated from high school at Stedelijk Gymnasium, Johan van Oldenbarnevelt 
in Amersfoort. After high school she began her study biological and neurological 
psychology at Utrecht University where she obtained her Master’s degree in 
2004. She subsequently began to work for Altrecht, Centre for Psychosomatic 
Medicine, where she worked as a clinician and a researcher in her job as a 
neuropsychologist.  In 2005 she worked also at the Psychodiagnostic Service of 
Altrecht. 
From 2008-2010 she studied a post-master Health Psychology at Altrecht, Centre 
for Psychosomatic Medicine and RINO Groep in Utrecht. Thereupon she kept 
working at Altrecht and started working at Merem, asthmacentre Heideheuvel 
as a General Health Care Psychologist and head of the department psychology. 
She then started her PhD at the Tilburg University in collaboration with Utrecht 
University, asthmacentre Heideheuvel in Hilversum and Revant, rehabilitation 
centre in Breda. 
In 2012 she started the post-master study Psychotherapist Specialist at 
Psychology Practice Bos en Lommer in Amsterdam and RINO Noord-Holland, 
which she graduated from in 2014. Subsequently she worked in her own 
practice as a psychotherapist. She now also works als a consulent at Merem, 
asthmacentre Heideheuvel. 
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Lonneke Kanters-Prins werd geboren op 2 maart 1981 te Zeist. In 2000 
behaalde ze haar VWO diploma aan het Stedelijk Gymnasium, Johan van 
Oldenbarnevelt in Amersfoort. Na het gymnasium begon ze met haar studie 
biologische en neuropsychologie aan de Universiteit Utrecht waar ze in 2004 
haar doctoraal behaalde. Na haar studie is ze in 2004 gaan werken bij Altrecht, 
Centrum Psychosomatiek voorheen Eikenboom waar ze zowel klinische als 
onderzoekswerkzaamheden uitvoerde als neuropsycholoog. Daarnaast heeft ze 
in 2005 een jaar gewerkt bij de Psychodiagnostische Dienst van Altrecht. Van 
2008-2010 volbracht ze de GZ-opleiding bij Altrecht, Centrum Psychosomatiek 
voorheen Eikenboom en de RINO Groep te Utrecht. Lonneke is vervolgens zowel 
bij Eikenboom blijven werken en gaan werken bij Merem, behandelcentrum 
Heideheuvel, een gespecialiseerd astmacentrum. Hier werkte zij als GZ-
psycholoog en vakgroepcoördinator van de afdeling psychologie. Naast haar 
werkzaamheden als clinicus begon ze met haar promotietraject  aan de 
Universiteit van Tilburg in samenwerking met zowel de Universiteit van Utrecht, 
Heideheuvel als Revant, voorheen Schoondonck, revalidatiecentrum te Breda. 
In 2012 startte ze met de opleiding tot psychotherapeut bij Psychologen 
Praktijk Bos en Lommer te Amsterdam en RINO Noord-Holland welke ze in 2014 
afrondde. Vanaf 2014 werkt zij enkel nog in eigen praktijk. Ze werkt sinds kort 
ook als consulent bij Merem, behandelcentrum Heideheuvel.
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